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1
1. CHAPTER 1: Introduction
1.1. Early Detection of Ovarian Cancer
1.1.1. Ovarian Cancer Subtypes, Stages, and Survival
Ovarian cancer is the fifth leading cause of cancer-related deaths in women.
Stage I ovarian cancer is defined by localized cancer in the ovaries or fallopian tubes,
with only 15% of cases diagnosed at this stage [143].

The majority of cases are

diagnosed at an advanced stage, defined as stage II when the tumor has spread to
organs within the pelvis, stage III which involves the peritoneal surface of the pelvis or
abdomen and surrounding lymph nodes, and stage IV with metastasis beyond the
abdominal cavity [143]. Worldwide, the 5-year age-standardized net survival for stage I
ovarian cancer is 80%, which decreases to 30% for advanced disease defined as stage
II-IV for all subtypes [119].

Standard of care is primary optimal debulking surgery

followed by platinum-based chemotherapy [9, 106]. The most significant prognostic
factor is degree of residual disease following surgery [106]. The majority of patients
with advanced disease experience a recurrence, of which 75% of recurrent cases
cannot be cured [106]. The presence of chemoresistant stem-like cells contributes to
tumor recurrence [96].
Ovarian cancer is classified as Type I and Type II, which represents 20% and
80% of cases, respectively. Type I ovarian cancer is less aggressive, low grade, is
associated with ARIDA1, BRAF, PIK3CA, PTEN, and KRAS mutations, and is
comprised of mucinous, clear cell, and endometrioid tumor subtypes. Type II ovarian
cancer has more aggressive, high grade tumors most commonly comprised of the
serous subtype, and is associated with p53 mutations [101]. The site of origin differs
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between Type I and Type II tumors; Type I tumors originate as atypical benign
conditions such as endometriosis which can implant on the ovary and transform,
whereas Type II tumors originate in the fallopian tube as serous tubal intraepithelial
carcinoma. Type I ovarian cancer is largely diagnosed at stage I or II whereas Type II
ovarian cancer is most often diagnosed at stage III or IV with decreased overall survival
[101]. Seventy percent of all epithelial ovarian cancer cases are high-grade serous
ovarian cancer (HGSOC); the present study evaluates a series of autoantibodies for use
as diagnostic biomarkers in serum samples from patients with HGSOC [143].
1.1.2. Early Detection in the General Population
Three large randomized control trials have evaluated the effectiveness of
screening for ovarian cancer in the general population. In the Prostate, Lung, Colon,
and Ovarian (PLCO) cancer trial, 68,557 women were followed [23]. Screening for
ovarian cancer was performed with both Cancer Antigen 125 (CA125) and transvaginal
ultrasound (TVUS).

Abnormal findings on either test prompted surgery, with no

observed mortality benefit compared with the control arm with no screening. CA125 is a
glycoprotein that was identified as a biomarker for ovarian cancer and is elevated in
80% of late stage cases and 50% of early stage cases [153]. It is also elevated in other
benign gynecological conditions such as uterine fibroids, endometriosis, as well as other
diseases such as cirrhosis and interstitial lung disease [4]. Alone, it is not an adequate
biomarker due to insufficient sensitivity and specificity. When measured at a single time
point, CA125 has historically been considered elevated at a level >35 U/mL, and has
been used to monitor recurrent disease. The PLCO trial utilized a single measurement
of CA125, and in the same time frame women underwent imaging with TVUS. Results
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of the PLCO trial showed no difference in mortality for this screening method [23]. A
randomized control study in Japan titled the Shizuoka Cohort Study of Ovarian Cancer
Screening (SCSOCS) enrolled 41,688 women who were either screened annually with
TVUS and CA125 interpreted at a single time point at the cutoff value of 35 U/mL [97].
An increased proportion of stage I cases was observed, though this finding was not
significant, and mortality was not reported [97].
Improvements in early detection were observed in the UK Collaborative Trial of
Ovarian Cancer Screening (UKCTOCS) due to improved screening methods by
incorporation of the Risk of Ovarian Cancer Algorithm (ROCA).

ROCA detects

increases in CA125 values over time relative to each patient’s baseline value, which
improves specificity. Additionally, imaging with TVUS is only initiated by increasing
CA125 values, which greatly reduces false-positives. The UKCTOS study enrolled over
200,000 patients, divided into a multi-modal screening arm using ROCA, a screening
arm with yearly TVUS, and a non-screening arm [86].

Multi-modal screening with

ROCA resulted in a stage shift with 36.1% detected at stages I-II [85]. Initial analysis at
7 years suggests there may be a mortality benefit in the ROCA screening arm, and
while follow-up long term analysis at 14 years remains to be reported, if trends observed
at 7 years continue there is predicted to be an observed mortality decrease in the
screening arm [86].
1.1.3. Early Detection in High Risk Population
Screening in increased-risk populations has the potential to be beneficial given a
higher prevalence relative to the general population [75, 147, 166]. Those with a family
history of ovarian cancer are at an increased-risk, including hereditary breast and

4
ovarian cancer patients with BRCA1 and BRCA2 mutations that are frequently found in
the germline of Type II HGSOC, and Lynch syndrome with mismatch repair gene
mutations [43]. The clinical recommendation for women with known BRCA1 or BRCA2
mutations or family history of ovarian cancer is prophylactic removal of the ovary and
fallopian tubes. Risk-reducing salpingo-oopherectomy (RRSO) reduces ovarian cancer
incidence in high risk women [146]. Among patients with BRCA1/2 mutations, those
who completed RRSO have reduced incidence of ovarian cancer and cancer-related
mortality rates [112]. However, the decision to undergo surgery is complex, and there
remains a population of women who choose not to undergo surgery. In a study of 2,287
women with increased familial risk of ovarian cancer, 40% of patients chose RRSO,
while 60% chose ovarian cancer screening with the ROCA screening strategy [112].
Risk of surgery, maintaining the option to have children, and both physiological and
psychological side effects of removal of the ovary and fallopian tube stemming from
surgical menopause including bone density loss and hormonal changes are factors that
patients consider. [56, 112, 123].

An increased risk of multi-morbidity has been

reported for patients undergoing bilateral salpingo-oopherectomy in a study comparing
1,653 women retaining ovaries with 1,653 women at average risk for ovarian cancer
who underwent surgery [144]. Women with the oophorectomy performed between the
ages of 46-49 had a significantly increased risk of anxiety, depression, hyperlipidemia,
diabetes, arthritis, and cancer. Women who underwent surgery before the age of 46
were also at a significantly increased risk for depression and hyperlipidemia, as well as
for cardiac arrhythmias, coronary artery disease, arthritis, asthma, chronic obstructive
pulmonary disease, and osteoporosis [144].
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For women who decide to not have surgery, 3 prospective trials have recently
examined the benefit of screening more frequently than once a year, and a stage shift
was observed in cases detected. In the UK Familial Ovarian Cancer Screening Study
phase II trial, 4, 348 women at high-risk for ovarian cancer were screened for CA125
every 4 months with yearly TVUS, which resulted in a significant stage shift in
diagnosis. Of the 19 total cases detected during the 5 years of screening, 10 were
stage I-II [147]. Two prospective trials from the Cancer Genetics Network and the
Gynecologic Oncology Group together screened 3, 962 women at high-risk for ovarian
cancer with CA125 screening every 3 months, followed by TVUS upon increases in
CA125 above the patient’s baseline. In these trials, 3 of the 6 incident cases were
stage I-II [166]. These trials also demonstrated compliance with frequent screening
among high-risk women.

Additional biomarkers such as autoantibodies can be

combined with CA125 to improve upon sensitivity in early detection. For women at
high-risk for ovarian cancer, an improved early detection method would provide the
option of frequent screening for those who decline or delay prophylactic surgery.
1.1.4. Strategies for Early Detection
Although screening in high-risk women who decline surgery using the two-step
ROCA as described above is an acceptable method for early detection in terms of
sensitivity, specificity, and positive predictive value (PPV), there are limitations in both
steps. In the first step of CA125 detection, 20% of all cases will not express CA125,
and 50% of early stage cases will not present with detectable levels of CA125 and are
missed by ROCA [5, 164]. In the second step, TVUS has limitations of detecting early
stage disease at low tumor volume as well as errors in interpretation. Improvement of
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the first step by additional biomarkers to complement CA125 and novel imaging
technologies can further develop early detection strategies. For example, additional
circulating antigens as well as circulating autoantibodies have been measured in
samples without detectable CA125 in retrospective studies. Novel biomarkers, imaging
technology, and CA125 companion markers are outlined below.
TVUS is the standard technique for imaging of the ovaries, however it is limited in
visualization of the fimbriae of the fallopian tubes and is unable to detect small lesions
[54]. Light-induced endogenous fluorescence can detect serous tubal intraepithelial
carcinomas from surgically removed tissue with 73% sensitivity. In vivo, falloposcopy
has been proposed to detect serous tubal intraepithelial carcinoma with light-induced
endogenous fluorescence [128].
Circulating tumor cells (CTCs) can be isolated from blood by targeting epithelial
antigens on the cell surface followed by sequencing. In a study measuring both CA125
and CTCs in 153 serial serum samples from 51 patients with epithelial ovarian cancer,
CTCs were demonstrated to be superior to CA125 detection with 90% sensitivity [208].
CTCs detected 93% of stage I disease compared with CA125 which detected 64% of
stage I samples.

However the ability to implement detection of CTCs into routine

practice is limited.
Cell-free circulating tumor DNA (ctDNA) can be amplified from blood samples
and sequenced for mutations as well as analysis of DNA hypermethylation, copy
number variation, and loss of heterozygosity [54]. CancerSEEK is a test combining
ctDNA and protein biomarkers, which demonstrated 98% sensitivity, however the
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majority of cases were advanced stage. The limitation however is in the time frame
required to process blood samples [114].
miRNA can be detected in circulation within extracellular vesicles or bound to
chaperone proteins, which make them stable analytes. Multiple panels of miRNA have
been identified with high performance of sensitivities of 62.4%, 86%, 75% and
specificities ranging from 92.9%, 83%, and 100%, respectively [53, 198, 209]. The
complementation of these panels with CA125 is not yet known, however in limited cases
it was shown that CA125 positivity was independent of miRNA panel positivity,
suggesting that these two strategies could be combined for an enhanced test.
Methods of detection using body fluids in proximity to the ovaries such as
isolation of DNA from tampons as well as uterine lavage have been performed to detect
TP53 mutations [54]. Endocervical brushings were analyzed from 245 patients with
ovarian cancer using PapSEEK, a test which examines 18 mutations or aneuploidy, and
resulted in 99% specificity relative to 714 healthy controls with 33% sensitivity for all
ovarian cancer cases, as well as 34% sensitivity among early stage cases. When using
intrauterine brushing, PapSEEK resulted in 100% specificity with 45% sensitivity for 51
ovarian cancer patients relative to 125 healthy controls; this study did not measure
CA125 [54].
There have been extensive studies of additional circulating antigens to
complement CA125, of which the antigen HE4 has been most promising.

The

European Prospective Investigation into Cancer (EPIC) cohort study enrolled over
200,000 women, of which 810 developed ovarian cancer [165].

CA125, CA72.4,

CA15.3, and HE4 were evaluated with the banked serum samples, and none of the
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markers performed better than CA125. HE4 was the only marker to marginally increase
sensitivity in combination with CA125 [165].

The advantage of H4 is the superior

specificity to CA125 [74]. Evaluation of serum samples from the UKCTOCS study, the
combination of HE4 and CA72.4 was able to detect 16% of CA125-negative cases,
however they were not detected with additional lead-time relative to CA125 [164].
1.1.4.1.

Autoantibody Biomarkers

When the tumor is at a small size, there may be insufficient amount of circulating
antigens to be detectable in serum or plasma. Autoantibodies are attractive biomarkers
as they can be detected from a simple blood test, and they are more stable than
circulating antigens. The long-term stability of autoantibodies in frozen serum allow for
prospective-retrospective research in biomarker discovery and validation stages using
banked serum samples.

Studies of autoantibody tests for ovarian cancer to

complement CA125 measurements and TVUS are currently ongoing.

A detailed

literature review revealed that eighty-five autoantigens have been evaluated for the
early diagnosis of ovarian cancer with ongoing studies seeking an optimal panel [61,
92].

Due to inter-tumor heterogeneity and variable immune responses, it will be

necessary to combine markers with the sensitivities of individual autoantibodies ranging
from 10-30% to create a panel of antigens with sufficient sensitivity.
An autoantibody response can be detected from microscopic lesions that are
undetectable with imaging. For example, the antibody associated with paraneoplastic
encephalitis, Ma2, has been detected in patients with pre-invasive, microscopic
intratubular germ-cell neoplasm unclassified type (IGCNU) [118].

In a study of 6

patients with encephalitis and positive for anti-Ma2 antibodies with no apparent tumor,
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all 6 patients were found to have pre-invasive, microscopic IGCNU [118]. In this study
we evaluated a set of antigens associated with paraneoplastic syndromes for their use
in the detection of autoantibodies for the early detection of ovarian cancer.

In a

prospective study of serum samples from the UKCTOCS study, autoantibodies to TP53
were detected 8.1 months prior to elevated CA125 detection and 9.2 months prior to
ROCA detection in 34 cases that were screen-positive with ROCA, and 22.9 moths prior
to diagnosis of ovarian cancer in the 9 cases that were screen-negative with ROCA
[194]. Autoantibodies to tumor antigens, produced at small tumor volumes, can be
combined with serum screening of CA125 to improve sensitivity in early detection.
1.2. Tumor Immunology
The immune response to a transformed cells has been described by Schreiber et
al. as a multistep process named “cancer immuno-editing” [154]. This theory describes
the complex interaction of the immune system components of the microenvironment
during tumor development, and the subsequent selection of tumor cells which evade the
immune response.

The three stages of immuno-editing are defined as elimination,

equilibrium, and escape, and are critical components of tumor biology.
1.2.1. Immunotherapy and Ovarian Cancer
The immune response and tumor immune microenvironment influence tumor
development and patient survival. Ovarian cancer has been shown to be immunogenic,
and trials are currently evaluating the potential for both immunotherapies targeting
tumor antigens and checkpoint blockade strategies [90, 116, 131].

The immune

microenvironment has reproducibly been associated with prognosis in ovarian cancer;
infiltration of lymphocytes correlates with survival [99, 207].

Presence of tertiary

10
lymphoid structures (TLSs) in the tumor periphery is associated with improved
prognosis for lung, colorectal, breast, prostate, and ovarian cancer [72, 125]. TLSs in
ovarian cancer are associated with local memory B cells at the tumor site, as well as
increased levels of immunoglobulin (IgG) [72, 125]. The presence of B cells at TLS is
associated with increased patient survival in ovarian cancer [72].
Treatment strategies involving adoptive transfer of T cells have been developed
for antigens associated with ovarian cancer, particularly NY-ESO-1.

Cancer-testis

antigens (CTAs) are ideal targets for immunotherapy due to their restricted expression
in healthy tissue and overexpression in the tumor. The quantity of available T cells
limits adoptive transfer therapy, whereas chimeric antigen receptor T (CAR-T) cells do
not have this limitation. Targets for CAR-T cell therapy include NY-ESO-1, MUC16,
Mesothelin, HER2, and folate receptor-alpha [89, 192].
NY-ESO-1 is also a target for cancer vaccines.

A group that is pioneering

strategies for immunotherapy in ovarian cancer has developed NY-ESO-1 vaccines
currently being evaluated in phase 3 trials. Usage of DNA methylation inhibitors to
epigenetically enhance expression of cancer testis antigens such as NY-ESO-1 and
LAGE-1 in combination with NY-ESO-1 vaccine and chemotherapy resulted in 6/10
patients with partial clinical response or disease stabilization [132, 190]. Response was
associated with increased NY-ESO-1 autoantibodies and NY-ESO-1 specific T-cells.
This group has also demonstrated an upregulation of immune checkpoint pathways
when either PD-1, LAG-3, or CTLA-4 were blocked by genetic ablation or antibodies in
a mouse model [81]. These studies indicate that combination of blockade strategies
can overcome local T-cell suppression.
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Other targets of local immune suppression in ovarian cancer include indoleamine-2,3,-dioxygenase (IDO) and vascular endothelial growth factor (VEGF).
Macrophages secrete VEGF. IDO promotes T cell differentiation to T-regs. One trial in
ovarian cancer patients in remission is evaluating the combination of an IDO inhibitor
with an NY-ESO-1 vaccine in effort to extend rates of remission [131].
Anti-PD-1 and anti-PD-L1 therapies as single agents have not been successful in
ovarian cancer.

However combination of PD-L1 and CTLA-4 showed improved

outcome relative to either agent alone. CTLA-4 antibodies in combination with
chemotherapy, radiotherapy, and PARP-inhibitors have shown improved efficacy, due
to the enhanced immune response driven by presentation of tumor cell antigens during
cell death. In a phase I/II clinical trial, the overall response rate for recurrent ovarian
cancer patients receiving the combination of Parp-inhibition and PD-1-inhibition was
45% for ovarian cancer patients with BRCA1/2 mutations compared with 25% for overall
patients with ovarian cancer [107].
Importantly, the success of immunotherapy has been seen primarily in recurrent
ovarian cancer patients, as these treatment strategies are in early clinical trial stages.
After several lines of chemotherapy, which is enrollment criteria for the majority of the
trials, patients can have T cell exhaustion and emergence of an immunosuppressive
tumor microenvironment.

There is rational hope that immunotherapy as a frontline

treatment could provide optimal outcomes [90, 116].
1.2.2. Normal B-Cell Development and Generation of Antibody Diversity
B cell receptors undergo two mechanisms of somatic mutation, recombination of
the heavy and light chain in the central immune system followed by somatic
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hypermutation in the peripheral immune system [82].

These mechanisms generate

random combinations at a scale to match the enormous diversity of possible amino acid
combinations encountered in the body. Generation of autoantibodies, or antibodies
against non-foreign self-antigens, occurs when there is a breakdown of central or
peripheral tolerance mechanisms.

Tolerance to a particular antigen is defined by

lymphocytes with receptors specific to the antigen that remain alive but not active.
There are a series of checks against auto-reactive IgG, but despite these checks,
healthy individuals can harbor low titers of antibody against self-antigens without
escalation of the response to autoimmune symptoms.
In the bone marrow, developing B cells generate unique receptors with
recombination from three gene segments, called V(D)J recombination. T cells also
undergo V(D)J recombination in the thymus. Up to half of the B cell receptors and T cell
receptors that result from V(D)J recombination bind with self-antigen [64]. In the bone
marrow, when an immature B cell binds with self antigen, recombination-activating gene
1 and 2 (RAG1 and RAG2) maintain expression and continue to participate in V(D)J
rearrangement in effort to edit the B cell receptor [64]. Should the B cell receptor
remain reactive with native self-antigen, the cell will be removed via clonal deletion.
Cell death is mediated by decreased expression of the B-cell-activating factor receptor,
which binds the growth factor B-cell-activating factor (BAFF), as well as increased
expression of the pro-apoptotic factor BIM [64].
T cell receptors recognize linear peptide fragments that are presented on MHC
molecules. In the thymus, T cell receptors that weakly bind MHC with self-peptide
survive receptor selection and are not further edited by V(D)J recombination, as RAG1
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and RAG2 genes are no longer expressed, whereas those that bind self-peptide too
tightly activate cell death [64]. Genetic susceptibility to autoimmune diseases can be
due to mutations in MHC molecules resulting in defective MHC binding to peptide and
therefore ineffective deletion of self-reactive T cell receptors.

The autoimmune

regulator protein, or AIRE, is a transcription factor responsible for expressing proteins
that are organ-specific to present to developing T cells. Genetic defects in AIRE can
also result in autoimmunity, a prominent example being decreased expression of insulin
in the thymus due to specific AIRE variants resulting in autoimmune diabetes [64].
The second mechanism that generates B cell receptor diversity is somatic
hypermutation of the B cell receptor, which occurs in germinal center follicles in the
peripheral lymphoid tissues [64, 82].

During this process, antibodies are edited to

increase the affinity for antigen binding, which is called affinity maturation. At this stage
B-cells differentiate to antibody-producing plasma cells and memory B cells.
Furthermore, antibodies can undergo class switch recombination in which the of the
heavy chain switches from IgM to IgA, IgH, IgE, IgD, and IgG with different effector
functions [82]. Loss of immune tolerance can occur at multiple stages of B and T cell
development.
1.2.3. Development of an Autoimmune Response
Both genetic and environmental factors contribute to the breakdown of central or
peripheral tolerance and the development of autoimmune conditions. Multiple genes
associated with antigen processing or immunoregulatory mechanisms are involved in
genetic susceptibility to autoimmune disease. In patients with autoimmune disease,
often it is not a single gene but an accumulation of defects in immunoregulatory genes
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that are epigenetically deregulated or harbor mutations. Variants in HLA genes that are
involved in antigen processing and presentation via the MHC complex account for half
of the known genetic risk loci for autoimmune diseases [156].
In addition to MHC alleles associated with inefficient epitope binding, it has also
been theorized that epitope conformation can reduce or enhance the interaction with
MHC.

Antigens that are intrinsically disordered have reduced affinity to MHC.

In

particular, nuclear antigens have been characterized as having disordered epitope
fragments, which is suggested to affect binding to MHC and may contribute to their
escape from deletion in draining lymph nodes [24, 139]. These structural characteristics
partially explain the overlap of those autoantibodies to nuclear complex proteins, DNA
binding proteins and RNA binding proteins detected in autoimmune conditions and in
cancer, where immune regulation is disrupted. DNA-binding proteins and dsDNA and
ssDNA when bound to antibodies can also form immune complexes that can trigger
stimulatory receptors. Additionally, the protein structure can contribute to the propensity
of certain antigens to become recognized as non-self proteins. This includes regions
prone to cleavage by Granzyme B, caspases, or cathepsins, which can expose
otherwise hidden epitopes [16].
Environmental factors include both the creation of an inflammatory and immunostimulatory microenvironment with cytokines and activating signals, as well as exposure
of cryptic epitopes via toxins or apoptosis. Bacteria or virus can contain epitopes that
are shared with self-antigens, and trigger an immune response against self-antigens
through molecular mimicry [16, 24].
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1.2.4. Tumor Associated Antigens
There are several conditions that can generate an antibody or immune response
to a tumor. This includes a breakdown of immune tolerance including genetic defects in
antigen processing and presentation or down regulation of regulatory mechanisms,
antigen overexpression or expression of an organ-specific antigen, changes in protein
structure resulting from mutations and post-translational modifications, and cell death
through tissue injury causing exposure of intracellular antigens [13].
CTAs are a highly immunogenic class of tumor-associated antigens, with
expression often restricted to germ cells of the testis at various stages of differentiation
[59]. Cancer stem cells express CTAs at higher levels compared with the bulk tumor
population [110, 163, 196]; several CTAs have been shown to be involved in early
stages of embryonic development.

There are a number of antibodies shared by

autoimmune disease and cancer.

For example TP53 autoantibodies have been

detected in systemic sclerosis and systemic lupus erythematosus, and autoantibodies to
c-myc have been detected in systemic lupus erythematosus and dermatomyositis as
well as several tumor types [15].
Normal expression of onconeuronal antigens is restricted to the brain and therefore
expression of these antigens by a tumor can trigger an immune response; unregulated
autoimmunity in this context results in a paraneoplastic neurological syndrome.
1.3. Paraneoplastic Syndromes
Paraneoplastic syndromes are a form of autoimmunity driven by antigen expression
by the tumor, which directly demonstrates the anti-tumor immune response.
Paraneoplastic neurological syndromes manifest when an unregulated immune
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response targets tumor antigens that are also expressed by neuronal or muscle cells.
These syndromes are diagnosed before detection of the tumor in 70% of cases [66]. In
cases where tumor antigens are shared with neuronal cells, referred to as onconeuronal
antigens, patients have symptoms affecting the central nervous system.

When the

antigen is shared with antigens in muscle cells or at the neuro-muscular junction,
patients have symptoms affecting the peripheral nervous system.

The antibodies

associated with these syndromes are more specific for the tumor type than for the
resulting syndrome.
Interestingly, paraneoplastic syndromes can result in spontaneous regression of
the tumor, and immunological symptoms can resolve upon surgical removal of the
tumor. Return of paraneoplastic syndrome symptoms can indicate recurrence of the
tumor.

Although paraneoplastic syndromes are rare, paraneoplastic autoantibodies

have been reported in patients with lung, breast and ovarian cancer without a
paraneoplastic syndrome.

For example, 16-25% of SCLC patients without a

paraneoplastic syndrome were found to have autoantibodies to the paraneoplastic
antigen HuD [93].
Paraneoplastic syndromes are categorized by neurologists into classical and
non-classical syndromes, as described in Table 1.1 and Table 1.2 [67].

These

definitions guide diagnosis of a definite paraneoplastic syndrome as being caused by an
underlying tumor.

In addition to the following criteria, other known causes of

neurological syndromes must be excluded to diagnose a definite paraneoplastic
syndrome. Classical paraneoplastic syndromes are highly associated with cancer, and
in diagnosis of classical syndromes investigation for tumor with imaging and other
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diagnostic tests is undertaken immediately.

Classical syndromes with diagnosis of

tumor within five years of presentation of symptoms with or without paraneoplastic
antibodies are considered definite paraneoplastic syndromes. Non-classical syndromes
are less often caused by an underlying tumor and therefore to be categorized as
paraneoplastic in origin, the syndrome should be accompanied by presence of
paraneoplastic antibodies and tumor diagnosis within five years of presentation of
symptoms.

Non-classical syndromes without presence of paraneoplastic antibodies

that resolve upon treatment of tumor may also be considered definite paraneoplastic
syndromes. Diagnosis of a classical or non-classical syndrome with no tumor detection
but with presence of well-characterized paraneoplastic antibodies can be considered
definite

paraneoplastic

syndrome;

these

cases

may

represent

an

effective

immunological tumor clearance [67].
1.3.1. Tumors Associated with Paraneoplastic Syndromes
The main tumor types associated with paraneoplastic syndromes are small cell
lung cancer, thymoma, breast, and ovarian cancer.

SCLC is the tumor type most

frequently detected in patients with paraneoplastic syndromes.

The syndromes

associated with SCLC are encephalomyelitis, cerebellar degeneration, opsoclonusmyoclonus,

sensory

neuropathy,

Lambert-Eaton

myasthenic

syndrome,

and

polymyositis as outlined in Table 1.1. The paraneoplastic autoantibodies associated
with SCLC are well characterized and can therefore be detected in 90% of SCLC case
with paraneoplastic neurological syndromes [65]. In a prospective study which included
n=240 SLCC cases without a paraneoplastic syndrome, 28.8% had detectable SOX2,
HuD, or P/Q voltage-gated calcium channel autoantibodies [65]. Of the 24 patients with
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a paraneoplastic neurological syndrome in the study, 87.5% were positive for at least
one those three paraneoplastic autoantibodies.
Thymoma

is

the

second

most

common

malignancy

associated

with

paraneoplastic syndromes. It has been reported that 30-47% of all patients with thymic
epithelial tumors, predominantly thymoma, develop the paraneoplastic syndrome
myasthenia gravis. Myasthenia gravis is the result of autoantibody interference in the
neuromuscular junction on skeletal muscle cells, which targets the acetylcholine
receptor (AChR) in 85% of cases. Autoantibodies against striated muscle antigens are
detected in the majority of patients with thymoma and myasthenia gravis.
Breast and ovarian cancer are associated with paraneoplastic cerebellar
degeneration with majority of the cases reporting with anti-Yo autoantibodies.

Yo

autoantibodies target both CDR2 (cerebellar degeneration related protein 2), also called
PCA-1 (purkinje cell antibody 1), and CDR2L (cerebellar degeneration related protein 2like), which shares 50% homology to CDR2 [52]. It has recently been reported that
CDR2L is the main target in paraneoplastic cerebellar degeneration, though Yo
autoantibodies can be detected with both antigens [52].

Benign teratoma, a non-

epithelial ovarian germ cell cancer, is the tumor type most commonly associated with
anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis, with reported 90% of
tumor-associated anti-NMDAR encephalitis cases having ovarian teratoma [32, 83,
202].
1.3.2. Etiology of Paraneoplastic Syndromes
The development of a paraneoplastic syndrome is a result of autoimmunity;
tumor associated antigens elicit an immune response to antigens also expressed in
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Table 1.1: Classical Paraneoplastic Neurological Syndromes.
Classical Neurological
Syndrome

PNS in association with Cancer and Onconeural Antibodies

References

Encephalomyelitis

Esophageal small cell carcinoma (anti-Hu), SCLC (anti-Amphiphysin)

[70, 161]

Limbic encephalitis

SCLC, breast (anti-Hu, anti-ANNA-3); Testicular cancer (anti-Ma2)
Gynecological and breast cancer (anti-Yo, anti-Ri); Lung (anti-Hu);
Hodgkin’s lymphoma (anti-Tr and anti-mGluR1); SCLC (anti-Zic4,
anti-ANNA-3)
Lung cancer (anti-Ri, anti-Hu, anti-Amphiphysin, anti-P/Q-type
Voltage-gated calcium channel (VGCC), breast and ovarian cancer
(anti-Ri, anti-Yo), testicular cancer (anti-Ma-2)

[71, 105]

SCLC (anti-Hu, anti-CV2(CRMP5), anti-Amphiphysin, anti-Yo)

[8, 47]

Thymoma (anti-Voltage gated potassium channel (VGKC))

[184]

SCLC (anti-P/Q type VGCC, anti-N-type VGCC, anti-SOX1, antiPCA2)

[105, 142,
150]

Lung, ovarian and breast adenocarcinoma (anti-Jo-1, anti-Mi-2)

[26, 203]

Syndromes of Central
Nervous System

Subacute cerebellar
degeneration
Opsoclonus-myoclonus
Syndromes of
Peripheral Nervous
System
Subacute sensory
neuropathy
Chronic
gastrointestinal
pseudo-obstruction
Syndromes of
Neuromuscular
Junction and Muscle
Lambert-Eaton
myasthenic syndrome
Dermatomyositis Polymyositis

[105, 158]
[14, 19, 77,
126]

Table 1.1: Paraneoplastic Syndromes and Associated Autoantibodies and Tumor Type.
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Table 1.2: Non-classical Paraneoplastic Neurological Syndromes.
Non-classical
Neurological
Syndrome
Syndromes of Central
Nervous System

PNS in association with Cancer and Onconeural Antibodies

References

Brainstem encephalitis
Optic neuritis caused
by Neuromyelitis
optica
Cancer-associated
retinopathy
Melanoma-associated
retinopathy

Lung carcinoma (anti-Ri, anti-Hu)

[19, 122]

Lung adenocarcinoma (anti-Aquaporin-4)

[183]

Lung cancer (anti-recoverin)

[140]

Melanoma (autoantibodies against rod bipolar cells)

[170]

Stiff person syndrome
Necrotizing
myelopathy

Breast cancer, thymoma, and colon cancer (anti-Amphiphysin)

[170]

Leukemia (No reports on well characterized onconeural antibodies)

[63]

Motor neuron diseases

Thymoma (anti-CV2(CRMP5))

[182]

SCLC (anti-Hu)

[151]

Lung adenocarcinoma (anti-CASPR2)
Breast cancer (No reports on well characterized onconeural
antibodies)

[176]

SCLC (anti-Hu)
Multiple Myeloma, non-Hodgkin’s lymphoma, chronic leukemias
(anti-MAG)

[113]

Gastric cancer (antinuclear cytoplasmic antibody (ANCA))

[36]

SCLC (anti-collapsin response mediator protein 5 (CRMP-5))

[127]

NSCLC (No reports on well characterized onconeural antibodies)

[178]

Thymoma (anti-acetylcholine receptor (AChR))

[206]

Thymoma (anti-VGKC)

[58]

Merkel cell carcinoma (MCC) (anti-Hu)

[78]

Syndromes of
Peripheral Nervous
System
Acute sensorimotor
neuropathy
Guillain-Barre
syndrome
Brachial neuritis
Subacute/chronic
sensorimotor
neuropathies
Neuropathy and
paraproteinaemia
Neuropathy with
vasculitis
Autonomic
neuropathies
Acute
pandysautonomia

[109]

[145]

Syndromes of
Neuromuscular
Junction and Muscle
Myasthenia gravis
Acquired
neuromyotonia
Acute necrotizing
myopathy

Table 1.2: Non-classical Paraneoplastic Syndromes and Associated Autoantibodies and
Tumor Type.
dneuronal or muscle tissues, breaking immune tolerance and resulting in
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neuronal or muscle tissues, breaking immune tolerance and resulting in autoimmune
tissue damage. The occurrence of antibodies in serum and cerebrospinal fluid (CSF)
that recognize the antigens shared by neurons and tumor cells has been reported,
however only a fraction of tumor-bearing patients with elevated titers of paraneoplastic
autoantibodies will develop a neurological syndrome. Cross-reactivity of tumor and
nervous tissue alone is insufficient to cause a paraneoplastic neurological syndrome
and other factors are necessary including enhanced cytokine production, increased
MHC-1 expression, and infiltration of CD8+ T-cells to the tissue site [44]. Like other
autoimmune diseases, development of paraneoplastic neurological syndrome is due to
a combination of environmental and genetic factors. There have been associations with
HLA haplotypes with increases susceptibility to paraneoplastic syndromes [162, 201].
Presumably, in patients with insufficient binding of epitopes to MHC proteins, there can
be errors in clearance and these epitopes can be allowed to persist undetected as a
self-antigen.
Somatic mutations in target antigens for paraneoplastic cerebellar degeneration,
CDR2 and CDR2L have been reported. Of 26 ovarian cancer cases with antibodypositive cerebellar degeneration, 65% of cases had at least one somatic mutation, and
59% also had CDR2L gene amplification [167].

All 26 cases had either gene

amplification or somatic mutation in the CDR2/CDR2L genes. Additionally, missense
mutations were predicted to have enhanced binding to MHC I. None of the 116 control
samples from patients with ovarian cancer without paraneoplastic cerebellar
degeneration harbored mutations in these genes [167].
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1.3.3. Autoantibodies Associated with Paraneoplastic Syndromes
1.3.3.1.

Intracellular Antigens

Intracellular antigens include anti-nuclear antibodies, such as DNA and RNA
binding proteins, and cytoplasmic antigens including tRNA synthetase antibodies, and
syndrome-specific antibodies. The symptoms of paraneoplastic syndromes involving
intracellular antigens are primarily the result of T-cell mediated destruction of healthy
tissue. This is evidenced by infiltration of CD8+ T cells in autopsied and biopsied tissue.
In patients with paraneoplastic cerebellar degeneration, paraneoplastic Yo antigen
specific cytotoxic T-cells have been detected in patient blood samples [2]. Symptoms of
paraneoplastic syndromes that target intracellular antigens including onconeural
antigens can be irreversible due to T-cell mediated death of neurons.
Studies have also shown antibody-uptake in rat brain neurons with functional
consequences, suggesting possible additional methods of neuronal death in addition to
cytotoxic T-cell targeted attack. Intracellular uptake and demonstrated binding of antiYo antibodies resulted in disruption of calcium homeostasis in rat cerebellar slice culture
[155]. Greenlee et al. has reported cellular uptake of both anti-Yo and anti-Hu patient
antibodies in rat slice culture [68, 69].
1.3.3.2.

Extracellular Antigens

In paraneoplastic syndromes that target membrane bound proteins, the
antibodies can be directly pathogenic. Antibodies target various neuronal cell surface
channels and receptors including: voltage-gated potassium channel-complex, ionotropic
glutamate receptors (iGluRs), metabotropic glutamate receptors (mGluRs), gammaaminobutyric acid (GABA), glycine receptor, and water channels [83].

Antibodies
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targeting the neuromuscular junction include voltage-gated calcium channels, muscle
AChR, and ganglionic AChR, as outlined in Tables 1.1 and 1.2 [83].
1.3.3.3.

Treatment

Autoantibodies targeting antigens located extracellularly on the cell membrane
can directly cause symptoms. Dalmau et al. reported that in paraneoplastic encephalitis
associated with NMDAR antibodies, a rapid correction of symptoms after surgery for
ovarian teratoma was observed [45].

The target antigens include extracellular

receptors, and in most cases the antibodies are directly pathogenic.

Therefore

removing or diluting circulating IgG provides benefit to these patients. Paraneoplastic
syndromes that target extracellular antigens are easier to manage with treatment
options such as intravenous immunoglobulin (IVIg) and plasma exchange therapy (PE).
IVIg consists of a blood-derived product collected from humans. The mechanisms of
action are not completely understood, but IVIg is involved in the inhibition of B cells and
production of autoantibodies as well as saturation of FcRn receptor, which is involved in
recycling of IgG through protection from lysosomal degradation [17, 168]. IVIgs have
been used in the treatment of some autoimmune diseases like Guillain-Barré.
Syndrome, chronic demyelinating polyneuropathy, and systemic lupus erythematosus
[168]. PE and immunoadsorption (IA) are procedures that help to remove circulating
antibodies. PE removes antibodies in a non-specific manner, whereas IA removes
antibodies with a high specificity due to the presence of an adsorber (commonly
tryptophan). A retrospective study revealed that in a study population of 31 patients who
had autoimmune encephalitis, 22/31 had autoantibodies against N-methyl-d-aspartate
receptor (NMDA-R), voltage-gated potassium channel (VGKC), Hu and GABA, and
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treatment with PE and IA showed an improvement in modified ranking score in 67% of
the patient population [51].
In contrast, the evaluation of IVIg treatment was reported by Uchuya et al. in a
retrospective study including 22 patients with anti-Yo and anti-Hu PEM and sensory
neuropathy, both intracellular targets. Stabilization was observed in 10% of patients who
received IVIg at a dose of 0.5 g/kg/day for 5 days, and was carried on for 3 months
[177]. Due to the primary involvement of CD8+ T cells and permanent loss of neuronal
cells, paraneoplastic syndromes targeting intracellular antigens such as cerebellar
degeneration have poor prognosis and can often be fatal. Treatment with IVIg or PE is
of little benefit for cases targeting intracellular antigens. Instead, immunosuppression
via steroids or depletion of lymphoid populations with immunotherapeutics such as
Rituximab can alleviate some symptoms.
1.3.4.

Immunotherapy and Neurological Adverse Events

1.3.4.1.

Mouse Models

The presence of autoantibodies alone is not sufficient to cause paraneoplastic
syndromes. This is reflected by the fact that the frequency of patients with cancer
positive for paraneoplastic autoantibodies is higher than the frequency of patients with
cancer who develop paraneoplastic syndromes as well as directly demonstrated by
mouse models where administration of autoantibodies is insufficient to cause disease.
A model involving CTLA4, however, was shown to invoke paraneoplastic syndrome
[200]. In this model, breast cancer cells expressing influenza hemagglutinin antigen
(HA) were implanted into balb/c mice. The mice expressed HA with cre recombinase in
Purkinje cells in the cerebellum.

CD4+ and CD8+ T cells with anti-hemagglutinin
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receptors were injected intravenously, and the tumor growth was decreased relative to
controls. The mice however did not express any neurological symptoms. When this
syngeneic mouse model was treated with anti-CTLA4, the anti-tumor response was
increased and in addition the mice displayed evidence of cerebellar degeneration both
behaviorally and with Purkinje cell loss with inflammation of the cerebellum. When mice
with HA-expressing tumor cells but without HA expressing purkinje cells were injected
with anti-hemagglutinin CD4+ and CD8+ T cells, treatment with anti-CTLA4 had
comparable affect on tumor regression but did not result in any neurological symptoms.
Similarly, administration of anti-PDL1 antibody in a mouse model for autoimmune
encephalomyelitis exacerbated the neurological symptoms.

This mouse model for

autoimmune encephalomyelitis is initiated by immunization to myelin oligodendroctye
glycoprotein peptide [152]. Increased infiltration of lymphocytes to the CNS as well as
increased antigen-specific T cell expansion and cytokine production were observed
after PD-1 blockade [152].
Mouse models with antibodies that target cell surface antigens however can
induce neurologic symptoms without inhibition of immune checkpoints. Autoantibodies
targeting mGluR from patients with paraneoplastic cerebellar degeneration were
injected into mice intrathecally and resulted in severe cerebellar ataxia in mice, which
was reversible with removal of the autoantibodies [205].
1.3.4.2.

Case Reports

Paraneoplastic syndromes are a form of autoimmunity driven by antigen
expression on the tumor, and they are a demonstration of the mechanisms of tumor
immunity. CAR T cell therapy can result in neurotoxicity, however this neurotoxicity is
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not caused by a paraneoplastic syndrome. Neurotoxicity associated with CAR T cell
therapies includes CAR T cell- related encephalopathy syndrome and cytokine-release
syndrome [129]. Therapies targeting immune checkpoints can result in immune-related
adverse events (irAEs), which includes paraneoplastic syndromes. Use of checkpoint
inhibitors has resulted in paraneoplastic syndromes to arise in tumor types not
otherwise associated with paraneoplastic syndromes, such as melanoma [205].
Dermatomyositis was diagnosed in a woman with metastatic melanoma who was
treated with CTLA-4 inhibitor ipilimumab.

The dermatomyositis symptoms resolved

when therapy was discontinued, and they returned when ipilimumab was again
administered [159].

In another case report of metastatic melanoma, a patient was

treated with both ipilimumab and nivolumab. Within two weeks of treatment, the woman
developed symptoms indicative of autoimmune encephalitis, and was treated with IVIG
and methylprednisolone [188]. The patient was tested for presence of paraneoplastic
antibodies, and NMDAR antibodies were detected in the cerebrospinal fluid.

After

treatment with rituximab, the patient’s symptoms improved [188].
A phase 2 clinical trial measured correlation of paraneoplastic antibodies with
neurotoxicity when SCLC patients were treated with the immuostimulatory agent
ipilimumab, which is an anti-CTLA-4 antibody targeting T-regulatory cells [10]. Results
indicated that presence of paraneoplastic syndrome associated autoantibodies at the
start of treatment correlated with severe paraneoplastic neurotoxic effects [10].

In

addition to early detection, assessment of paraneoplastic autoantibodies may provide
candidate biomarkers as there are increasing calls for predictive baseline biomarkers to
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identify patients at risk for developing neurologic irAEs prior to treatment with
checkpoint inhibitor immunotherapies.
1.3.5. Paraneoplastic Syndromes Associated with Ovarian Cancer
The paraneoplastic syndromes most commonly associated with ovarian
carcinoma include paraneoplastic cerebellar degeneration, dermatomyositis and
polymyositis [202, 203]; women presenting with these syndromes are referred for
evaluation of ovarian cancer. Symptoms of cerebellar degeneration include ataxia, lack
of balance, speech dysfunction, and nystagmus.

Antibodies associated with

paraneoplastic cerebellar degeneration that have been detected in women with ovarian
cancer include anti-Yo, anti-Ri, and anti-Amphiphysin [202].

Polymyositis is an

inflammatory myopathy resulting in muscle weakness, in cases of dermatomyositis, skin
rashes co-occur with muscle weakness. Patients with these symdromes are at higher
risk for malignancy, with detection of a tumor in 30% of dermatomyositis cases and in
15% of polymyositis cases [157]; relevant antibodies include anti-Jo1, anti-mi2, and
anti-SRP [105]. Paraneoplastic autoantibodies that have been reported in cases with
ovarian cancer are listed in Table 1.3. The presence of paraneoplastic autoantibodies
is criteria for diagnosis of a paraneoplastic syndrome in patients with neurological
symptoms, meaning the neurological syndrome is caused by the tumor-initiated immune
response. However, paraneoplastic autoantibodies can also be detected in serum from
patients with a tumor that do not present with neurological symptoms.

Therefore,

detection of autoantibodies associated with paraneoplastic syndromes is an approach to
the early detection of ovarian cancer in asymptomatic patients.
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Table 1.3: PNS Autoantibodies Reported in Ovarian Cancer Cases.

PNS in association with
ovarian cancer
Paraneoplastic cerebellar
degeneration
Paraneoplastic cerebellar
degeneration
Paraneoplastic cerebellar
degeneration
Paraneoplastic Cerebellar
Degeneration
Paraneoplastic
encephalomyeloneuropathy
Encephalomyelitis
Myositis
Myositis
Myositis, Myasthenia gravis
Dermatomyositis
Dermatomyositis
Paraneoplastic Cerebellar
Degeneration
Idiopathic inflammatory
myopathy, Sjogren’s syndrome
and SLE
Antiphospholipid antibody
syndrome

Onconeural antibodies targeting
paraneoplastic antigens in PNS-associated
ovarian cancer
Yo antibody or Purkinje cell cytoplasmic
antibody type 1 (PCA-1/CDR2)
Zic-4 antibodies

NCBI
NM_001802
BC136339

Carbonic anhydrase-related protein VIII
(CARP VIII) antibodies

NM_004056

Creatine kinase B (CKB) antibodies

NM_001823

P/Q and N type calcium-channel antibodies

X99897
M94172
NM_001635

Amphiphysin antibodies
Jo-1 autoantibodies, Histidyl-tRNA
synthetase (HARS)
SRP-19 autoantibodies
Cortactin antibodies
TIF1-γ (TRIM33) autoantibodies or antip155/140
NXP-2 autoantibodies, or anti-MJ antibodies

Refs
[130]
[80,
95]
[1,
11]
[174]
[104]
[199]

AAX99363.1

[203]

U51920.1
BC008799.2

[73]
[18]

NG_023287.1

[117]

NM_015358.2

[84]

Yo antibody (CDR2L)

NM_014603

[52]

Ro52 autoantibodies (TRIM21)

NM_003141.3

[55,
149]

Phospholipid antibodies

N/A

[148]

Table 1.3: Paraneoplastic Autoantibodies Reported in Ovarian Cancer. Table adapted
from “Chatterjee M, Hurley LC, Tainsky MA. Paraneoplastic antigens as biomarkers for
early diagnosis of ovarian cancer. Gynecol Oncol Rep. 2017;21:37–44.”.
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1.3.6. Polymyositis/Dermatomyositis
Dermatomyositis and less commonly polymyositis are paraneoplastic syndromes
that can precede the diagnosis of ovarian cancer. The pathogenesis of polymyositis is
mediated by cytotoxic T-cells, as evidenced by an infiltration of CD8 + T-cells in the
muscle of myositis patients, which are recruited by local inflammation [25]. Additional
symptoms in dermatomyositis are caused by immune-complexes binding to endothelial
cells, activating the complement system and resulting in cell lysis and capillary
destruction through the membrane attack complex [25].
In paraneoplastic myositis, the target of immune attack is regenerating muscle
tissue, where in times of injury and muscle repair there is exposure of intracellular
antigens. It has been shown that the paraneoplastic antigens HARS and mi-2 are found
at high levels in developing muscle and myositis muscle, compared with low levels in
healthy muscle [26]. In vitro studies demonstrated that HARS and mi-2 were expressed
at high levels in myoblasts, and decreased as these cells differentiated to form
myotubes [26]. In addition to analysis of antigens in myositis muscle tissue and human
myotube cell culture, increased expression of myositis-associated antigens was
observed in regenerating mouse muscle [138].

Additionally, HARS expression was

found to be higher in the muscle of newborn rats compared with adult tissue [204].
1.3.6.1.

Myositis-Associated and Myositis-Specific Autoantibodies

The Jo-1 autoantibody that recognizes the Histidyl-tRNA synthetase (HARS) is
an antibody specific to myositis [203]. Chatterjee et al. have independently identified an
epitope of the anti-Jo-1 target, HARS, through a phage-display screening of serum IgGs
obtained from ovarian cancer patients. This epitope, when combined in a panel of 3
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antigens, had the ability to predict ovarian cancer recurrence 9 months prior to the
standard clinical recurrence criteria including CA125 [27].
Other autoantibodies found in the serum of myositis patients include anti-Ro52,
anti-PL-7, anti-PL-12, anti-Mi-2, anti-PM-Scl75, anti-PM-Scl100, and anti-Ku [41].
Patients with inflammatory myopathies that are positive for anti-Jo-1 are often positive
for anti-Ro52 antibodies, which target the antigen TRIM21. In one study examining the
sera of 112 patients with inflammatory myopathies, 21% of patients were anti-Jo-1
positive, 20% of patients were anti-Ro52 positive, and 58% of those anti-Jo-1 positive
patients were also positive for anti-Ro52 [149].

In a study of 89 anti-Jo-1 positive

patients with anti-synthetase syndromes including polymyositis and dermatomyositis, 36
were also Ro52 positive. It was also found that when Jo-1 and Ro52 antibodies cooccurred, the risk of malignancy was increased, with reported cases of colon, breast,
ovarian, and esophageal cancer [115]. Therefore, these two antigens together on a
panel could increase cancer diagnostic specificity of an autoantibody classifier.
Ishikawa et al. reported a study of screening of patients with connective tissue disease
including myositis and dermatomyositis for the detection of autoantibodies that target
nuclear matrix protein 2 (NXP-2). Out of 206 patients screened, 6 were positive for
NXP-2. The study showed that 1 out of these 6 patients had dermatomyositis diagnosed
at the same time as diagnosis of ovarian cancer. The patient was negative for
antibodies to transcription intermediary factor-1 gamma (Tif1-gamma) but positive for
antibodies to NXP-2 [84]. In another study of patients with inflammatory myopathies
screened against an inflammatory myopathy immunoprofile test, 11/80 patients tested
positive for an inflammatory myopathy associated antibody, and 5/11 of those patients
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had a cancer. Out of these 5 cancer cases with positive inflammatory myopathy
immunoprofiles, 1 of the cases was a woman with ovarian cancer who tested positive
for Tif1-gamma [117]. Fiorentino et al. reported that in a cohort of 111 patients at the
Stanford University Dermatology Clinic and a cohort of 102 patients at the Johns
Hopkins Myositis Center, positivity to either NXP-2 or Tif1-gamma was present in 83%
of patients with Cancer-Associated Dermatomyositis [57]. Suzuki et al. reported the
presence of anti-SRP54 antibodies in 100 patients who had an inflammatory myopathy,
5 of whom had a malignancy, including 1 ovarian cancer [169]. In these studies we
investigated a panel of autoantibodies associated with myositis for potential ovarian
cancer biomarkers.
1.3.7. Paraneoplastic Cerebellar Degeneration
In ovarian cancer-associated cerebellar degeneration, cytotoxic T-cell attack is
targeted to the Purkinje cells of the cerebellum. Destruction of Purkinje cells affects
speech and motility, and often results in patient death.

Case reports have

demonstrated otherwise undetectable microscopic ovarian cancer in patients with Yopositive cerebellar degeneration, which was discovered upon laparotomy and
pathological analysis of resected tissue, prompted by diagnosis of cerebellar
degeneration [62, 135]
1.3.7.1.

Autoantibodies Associated with Cerebellar Degeneration

Yo antibody is also known as Purkinje cell cytoplasmic antibody type 1 (PCA-1),
is targeted against CDR2 antigen that with limited normal protein expression in the brain
and testes, as well as overexpression in ovarian cancer with or without cerebellar
degeneration [38]. CDR2L (a member of CDR family) has 50% amino acid sequence
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homology to CDR2 and its expression has been observed in both ovarian tissue and
cerebellar Purkinje cells. Eichler et al. has reported that in a study population
comprising patients with ovarian cancer, breast cancer and paraneoplastic neurological
syndrome patients with Yo-positive antibodies, those patients who had paraneoplastic
cerebellar degeneration, harbored antibodies directed against both CDR2 and CDR2L
[52]. Darnell et al. reported that the tumor-specific expression of CDR2 in neurologically
normal patients with ovarian cancer. In this study, tumor specimen lysates were
prepared from 20 ovarian cancer patients were probed with sera obtained from
paraneoplastic cerebellar degeneration patients on western blot and 13/20 tumor
lysates showed the expression of CDR2 (target of anti-Yo antibodies) both in cerebellar
neuronal tissue and ovarian tumors [46]. Expression of CDR2 was also observed in
ovarian cancer patients who had no clinical manifestation of paraneoplastic cerebellar
degeneration or circulating anti-Yo antibodies [46]. Therefore, the expression of
onconeural antigens and their association with their respective antibodies does not
always associate with the appearance of paraneoplastic neurological syndrome [46].
Monstad et al. determined the prevalence of Yo antibodies in a study population
comprising 557 ovarian cancer patients and 253 breast cancer patients, few of which
were associated with paraneoplastic neurological syndrome. The frequency of Yo
antibody association with ovarian cancer was found to be 13/557 (2.3%), as opposed to
4/253 (1.6%) patients with breast cancer. Only 2/13 ovarian cancer patients had
paraneoplastic cerebellar degeneration prior to diagnosis of ovarian cancer [124]. For
paraneoplastic autoantibodies to be clinically useful for ovarian cancer diagnostics,
panels of multiple antibodies will need to be employed. Karasnoudis et al. reported a
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case study of a 60-year patient who initially had paraneoplastic cerebellar degeneration.
After performing paraneoplastic antibody screening, only Zic4 antibody titer in serum
was found to be elevated. CSF also showed presence of Zic-4 antibodies. Thoracic and
abdominal CT scans revealed the presence of a tumor in the right ovary and diagnosis
of ovarian adenocarcinoma was confirmed [95].

Hoftberger et al. reported the

appearance of carbonic anhydrase-related protein VIII (CARP VIII) antibodies in
association with paraneoplastic cerebellar degeneration at the time of ovarian
adenocarcinoma tumor recurrence in a 69-year woman [79].

CARP VIII protein is

expressed in the brain Purkinje cells, however strong expression of CARP VIII protein
has been observed in lung cancer and has been linked to its higher proliferative and
invasive properties that are essential for tumor growth and progression [1]. Lennon et
al. investigated the frequency of anti-P/Q and N type calcium-channel antibodies in a
study population of cancer patients. Of 70 small-cell lung, ovarian or breast carcinoma
patients who were associated with a paraneoplastic encephalomyeloneuropathy, 2/19
(5%) ovarian cancer patients were reported to harbor antibodies against P/Q-type and
N-type calcium channels. The calcium channel antibodies were detected in human
cerebellar and cerebral cortical tissues [104]. Antoine et al. reported the occurrence of
Amphiphysin antibodies in ovarian cancer patients in a study comprised of 2800
patients but only 5 were selected after pre-screening the sera for the presence of
Amphiphysin antibodies. Among 5 patients, who were diagnosed with encephalomyelitis
prior to ovarian cancer diagnosis, one was found to have circulating Amphiphysin
antibodies [7]. A case report by Forgy et al. revealed that an ovarian cancer patient
developed paraneoplastic cerebellar degeneration symptoms at seven months post-
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surgery despite the fact that her CT scan report, CA125 levels, and physical
examinations indicated no recurrence of ovarian cancer, yet her levels of Yo antibodies
in the serum and in the CSF were both > 320 U/ml (normal range is < 10 U/ml) [60].
1.3.8. Paraneoplastic Autoantibodies Previously Associated with Ovarian
Cancer
In addition to classical paraneoplastic autoantibodies associated with myositis or
cerebellar degeneration, additional paraneoplastic autoantibodies have been reported in
ovarian cancer primarily in case studies as summarized in Table 1.3.
1.3.9. Sero-Negative Samples for Identification of Novel Paraneoplastic
Antigens
Although paraneoplastic antibodies known to be associated with cancer have
been studied in detail, the search for new paraneoplastic cancer associated
autoantibodies is ongoing. Novel antigens involved in central nervous system synaptic
or neuronal surface autoantibody disorders have recently been identified at an
approximate rate of two per year [103]. Two recent findings include antibodies to
cortactin and creatine kinase brain type (CKB) [18, 174].

Cortactin was recently

identified as a paraneoplastic antigen in two independent studies [18].

Following

identification, both groups screened paraneoplastic sera against cortactin; one group
detected cortactin antibodies in 20% of polymyositis patients using ELISA with western
blot confirmation, while the other group identified cortactin antibodies in 19.7% of
myasthenia gravis patients who were sero-negative for classic paraneoplastic antigens
[18].

Myositis is a paraneoplastic syndrome closely linked with ovarian cancer.

Cortactin has been reported to be overexpressed in ovarian cancer by mRNA analysis
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of tumor tissues as well as by immunohistochemical staining of cortactin on tumor
histological sections, and its expression was associated with poor prognosis [108].
Another recently identified paraneoplastic antigen is creatine kinase brain type, CKB. In
an effort to identify novel paraneoplastic antigens in patients with cerebellar
degeneration that were sero-negative for classic paraneoplastic markers, 2D western
blot of paraneoplastic antibody sero-negative sera followed by mass spectrometry
identified CKB as a novel paraneoplastic cerebellar degeneration-associated antigen
[174].

CKB serum antibody reactivity was demonstrated in the cytoplasm of mice

Purkinje cells as well as urinary bladder cancer tissue samples. CKB was elevated in
several cancers including stage 1 ovarian cancer patients and was demonstrated to
contribute to cancer progression [108]. As more paraneoplastic antigens are
discovered, the panel of antigens to use for diagnosis of ovarian cancer could be
expanded.
1.4. Paraneoplastic Antibodies for Early Detection
1.4.1. Paraneoplastic Antibodies as Cancer Biomarkers
As lung cancer is associated with paraneoplastic syndromes, an FDA-approved
ELISA based test for smokers at risk for lung cancer, the EarlyCDT-Lung panel of
antigens for the autoantibody detection of lung cancer, includes the paraneoplastic
autoantigens HuD and SOX2. HuD and SOX2 are associated with limbic encephalitis,
sensory neuronopathy and Lambert-Eaton myasthenic syndrome, and HuD is also
associated with paraneoplastic encephalomyelitis and paraneoplastic cerebellar
degeneration [65]. The sensitivity of the EarlyCDT-Lung 7-marker panel including HuD

36
and SOX2 is 41%, and in an audit of its first 1,600 screenings in the clinic, 57% of testpositive cases were early stage I or stage II NSCLC [87].
Cui et al., reported a study on autoantibodies to the paraneoplastic antigen Ma2
for the early detection of recurrence for small intestine neuroendocrine tumors (SINETs). The study evaluated 124 serum samples obtained from patients diagnosed with
SI-NETs on an ELISA platform with recombinant Ma2 protein, which resulted in high
sensitivity and specificity as revealed by the ROC values between 0.734 and 0.816 [42].
1.4.2. Panel of Autoantibodies for Early Detection
It is well established that while individual autoantibodies have low frequency of
positive titer among patient sera, a combination of autoantigens for detection of
autoantibodies can greatly increase diagnostic sensitivity. Matt et al. developed a
multiplex Luminex assay using six onconeuronal antigens, namely NOVA-1 (Ri
antibodies), HuD, Ma2, CDR62 (Yo antibodies), CRMP-5 (CV2 antibodies), and
Amphiphysin to immunoscreen 119 patients who had definite paraneoplastic syndrome.
Their assay yielded a high sensitivity, such as 83% for Ri antigen, 91% for Ma2, 93% for
HuD and 100% for Yo, CV2 and Amphiphysin. Higher specificity was also obtained, like
96% for CV2, 97% for HuD, Yo, Amphiphysin, 99% for Ma2 and 100% for Ri antigens
[111].

In a review of 60 ovarian cancer biomarker publications, of the 27 studies

involving TAA or autoantibody multi-analyte panels, it was demonstrated that improved
sensitivity with a panel of markers can be achieved while maintaining specificity [160].
Therefore a panel of multiple antigens should increase the sensitivity of antibody-based
tumor diagnostics, and in the case of ovarian cancer, a panel including paraneoplastic
antigens could serve to detect autoantibodies in high-risk populations with family history
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or known BRCA1/2 mutations. A panel of autoantibodies could be measured CA125;
both the antigen and antibodies could be analyzed from a patient serum sample. Other
cancers, especially those associated with paraneoplastic syndromes such as breast,
lung, pancreatic, colon, and lymphoma, could benefit from TAA combined with
autoantibody detection.
1.4.3. Methods of Detection of Autoantibodies
The evaluation of onconeural antibodies in ovarian cancer serum samples with or
without paraneoplastic syndrome was used to generate a panel of paraneoplastic
antigens to implement in screening on various clinical platforms. Standard approaches
for the detection of autoantibodies in patient serum are ELISA and western blot [13].
Immunohistochemistry and cell-based fluorescence are also used in particular for
intracellular onconeuronal antigens. Rat and primate brain slices are commonly used
for expression patterns of neuronal cell-surface antigens [179] . Immunohistochemistry
however is difficult to interpret and subject to user bias. Immunocytochemistry is also
used on cultured rat hippocampal neurons. Cell-based assays using transformed cells
such as HEK or HeLa cells overexpressing the target antigen can be incubated with
patient serum and measured for staining [179].
More sensitive and rapid tests have recently been developed for autoantibody
detection, including electrochemical, optical, and microfluidic approaches [191]. Optical
approaches include surface plasmon resonance (SPR), localized surface plasmon
resonance (LSPR), and surface enhanced Raman spectroscopy (SERS) [191].
For autoantibody discovery phases, mass spectrometry is a reliable method,
particularly with Serologic Proteome Analysis (SERPA) in which tissue homogenate or
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cell lysates are separated on a 2D SDS PAGE gel, and spots specific to disease
samples are analyzed by mass spectrometry. Serological analysis of recombinant cDNA
expression libraries (SEREX) has historically been used for discovery of many tumorassociated antigens, including NY-ESO-1 [13, 33].

Protein microarrays are an

improvement from SEREX in that these arrays utilize purified recombinant protein,
eliminating much of the background noise generated from using E. coli cell lysates in
SEREX.

A prominent example of a human protein microarray is Nucleic Acid

Programmable Protein Arrays (NAPPA) [13].
1.5. Hypothesis: Autoantibodies Associated with Paraneoplastic Syndromes
are Candidate Biomarkers for Early Detection of Ovarian Cancer
As paraneoplastic antigens initiate autoimmune responses, these are highly
immunogenic proteins expressed by the tumor. While paraneoplastic syndromes are
rare, autoantibodies associated with the syndromes are more common. In SCLC, 1625% of cases without a paraneoplastic syndrome had detectable anti-Hu antibodies,
and 40% of SCLC cases without a neurological syndrome had a detectable levels of at
least one paraneoplastic antibody from a panel of intracellular and cell surface antigens
[65, 93].

Therefore, we evaluated a set of myositis associated and onconeuronal

autoantigens for detection of autoantibodies in serum from ovarian cancer patients
without a known paraneoplastic syndrome.
The primary goal of this thesis is to identify candidate autoantibody biomarkers
for early detection of ovarian cancer. In addition to early detection, understanding the
distribution of autoantibodies in patients without neurological symptoms may help to
further understand development of paraneoplastic syndromes as well as management
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of immunotherapy neurologic irAEs. Baseline levels of paraneoplastic autoantibodies
could serve to identify patients that would be at risk for developing neurologic irAEs as
immunotherapies for ovarian cancer treatment continue to develop.
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2. CHAPTER 2: Materials and Methods
2.1. Collection of patient samples
Samples were obtained from patients at Karmanos Cancer Institute, St. John
Hospital and Oakwood Hospital in Detroit, MI, and at the Mayo Clinic, Rochester, MN.
Additional specimens were provided by the Cooperative Human Tissue Network
(CHTN) and Gynecologic Oncology Group specimen banks. All samples were collected
prior to surgery or therapy. Healthy control sera were collected as part of a large-scale
community outreach project.

Blood was collected via venipuncture, centrifuged at

2,500 rpm at 4°C, and the resulting serum stored at -80°C.

Protocols were approved

by the Institutional Review Boards of Wayne State University and the individual
hospitals. Each patient provided written informed consent.
For the Validation I and Validation II studies, the early and late stage HGSOC
group is comprised of females age 18 and over diagnosed with epithelial ovarian
cancer. In these studies we used serum collected from 19 early stage and 95 late stage
serous ovarian cancer patients prior to treatment or surgery. The benign ovarian cyst
group included 100 samples. One hundred healthy controls were self-reported to be
free of cancer and potentially confounding benign conditions such as ovarian cysts,
uterine fibroids, or endometriosis. The HARS antigen was not processed with the
Validation II sample set, with the exception of n=5 early stage HGSOC samples.
Sample usage tracking ensured that the 314 samples selected for the two validation
studies were not used initially to identify the biomarkers.
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2.2. Sub-cloning of Antigens
The tumor antigens were first PCR amplified using forward primers (containing
6X His tag and T7 tags) and reverse primers using cDNA template obtained from
ovarian tumor samples or ovarian cancer cell lines SKOV3 or OVCAR3. The PCR
products were column purified, digested with restriction endonucleases and ligated to
pET-21b bacterial expression vector (EMD Millipore Corporation, San Diego, CA)
(Figure 2.1). The ligated DNA was then transformed into the BL21-DE3 strain and
positive colonies were selected; all cDNA expression plasmids used in this study were
fully DNA sequenced. These expression vectors were employed for in vivo production of
recombinant His-tagged proteins in Bl21-DE3 bacterial strain.
2.3. Purification of Antigens
The BL21-DE3 bacterial cells bearing clones were grown overnight in 5 mL LB
with 50 µg/mL ampicillin at 37° C. 0.5 mL of the overnight culture was added to 500 mL
LB with 50 µg/mL ampicillin and grown at 37° C to OD between 0.4-0.5, IPTG (β-D-1thiogalactopyranoside) was added to a final concentration of 0.6 mM to induce the
production of T7 RNA polymerase within the BL21-DE3 expression host, which is
required for RNA and subsequent protein synthesis and the culture was grown at 37° C
for three hours. The cells were pelleted at 1,200 X g for 15 minutes and supernatant
was discarded. The pellet was frozen at -80°C for at least 30 minutes and then lysed
with Thermo Scientific Bacterial Protein Extraction Reagent lysis buffer, centrifuged at
15,000 X g and then transferred the supernatant. The pellet, containing the target
protein that forms within inclusion bodies, was solubilized in 8M urea.
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2.3.1. HIS-Tag Purification
The crude His-tagged proteins were purified first using Ni-NTA beads (Thermo
Fisher Scientific, Waltham, MA) following manufacturer’s protocol. Ni-NTA beads bind
to His residues that are attached to proteins and results in relatively pure protein.
Western blot image of elutions of His-Purification are shown in Figure 2.1; elutions were
pooled and quantified with Bio-Rad DC protein assay.
2.3.2. T7-Tag Purification
The Ni-NTA purified His-tagged proteins were further purified using T7•Tag®
Antibody Agarose (MilliporeSigma, Burlington, MA) which bind the N-terminal 11 aa of
the T7 gene 10 protein. The second round of purification with T7 Antibody bound
agarose beads is necessary to remove any contaminating bacterial poly-His containing
proteins from first round of Ni-NTA bead purification. Following purification, proteins
were processed through Zeba desalting columns (Thermo Fisher Scientific, Waltham,
MA). Western blot image of elutions of T7-Purification are shown in Figure 2.1; elutions
were pooled and quantified with Bio-Rad DC protein assay.
2.3.3. Commercial Proteins
The recombinant proteins in this study are full-length, with the exception of the
recombinant PAX8 protein that consists of the amino acids 1-287 (Sino Biological,
Wayne, PA). The SRP-19 expression plasmid was kindly gifted by Dr. Howard M.
Fried, University of North Carolina at Chapel Hill [76].

The human TP53 (1-393)

expression plasmid was a gift from Cheryl Arrowsmith (Addgene plasmid #24859;
RRID:Addgene_24859; http://n2t.net/addgene: 24859) [12].
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Figure 2.1

Figure 2.1: Protein Purification Overview.
A. PET-21b vector map. B. Elutions of T712A antigen, His-column purification, anti-HIS
Ab 1:10,000. C. Elutions of T712A antigen, T7-agarose purification, anti-HIS Ab 1:10,000
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2.4. Western Blot
Western blots were performed with 0.5 µg of purified recombinant proteins
separated on a 10% acrylamide SDS-PAGE.

Proteins were transferred onto

nitrocellulose membranes for one hour on ice at 250mA. The membranes were blocked
overnight at 4°C with 5% milk in TBS with 0.1% Tween20 (TBS-T). The next day, each
serum sample was pre-incubated at a 1:300 dilution in 3 ml of 5% milk in TBS-T with 75
µg of BL21-DE3 E. coli lysate for one hour to reduce background reactions of human
sera to E. coli proteins.

The patient serum was then incubated with nitrocellulose

membranes for one hour at room temperature. Following three washes with TBS-T,
secondary IR-dye labeled mouse anti-His tag and goat anti-Human IgG antibodies were
incubated for one hour at room temperature followed by three washes with TBS-T and
two with PBS. Autoantibody binding to the antigens was quantified on LiCor Image
Studio software (LI-COR Biosciences, Lincoln, NE) as background-corrected integrated
intensity of anti-human IgG (IRDye800) normalized to anti-His tag antibody (IRDye700).
Secondary anti-HIS tag antibody was quantified and used as a loading control to
normalize each protein band to the anti-human IgG value.

The same lot of each

secondary antibody was used for the experiment, and separate preparations of
secondary antibody had no significant effect. Day to day variation as calculated from
the IRDye700 readings of the anti-His tag antibody was used to adjust data.
2.5. ELISA
2.5.1. Optimization of ELISA for Patient Serum Incubation
A semi-automated ELISA was developed using the Biomek3000 liquid pipetting
robot for addition of blocking reagent, washing buffer, secondary antibody, TMB
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substrate, and sulfuric acid. Plates were coated with antigen with multichannel pipette
by hand, and primary antibody consisting of patient serum diluted in blocking buffer was
added with a single channel pipette by hand.

Optimization was performed for:

concentration of coating antigen, dilution of patient samples, blocking reagent with
patient samples, and timing of the washing procedure including plate drying times
dependent on plate processing order.
2.5.1.1.

Selection of Blocking Agent

In order to optimize ELISA conditions, we processed plates with a number of
blocking reagents. The blocking reagents evaluated at various concentrations each
included:

casein, gelatin, donkey serum (Jackson Laboratories), Donkey Serum

(Equitech-Bio, Kerrville, TX), Aves Blocking buffer, Chonblock, Seablock, BSA, Milk,
and keyhole limpet haemocyanin (KLH).

We found that the donkey serum from

Equitech-Bio at 5% provided the lowest background.
2.5.1.2.

Serum Sample Preparation

Our primary antibody in this indirect ELISA was patient serum diluted 1:300.
Originally, patient serum was diluted in washing buffer. However we observed that a
number of samples displayed reactivity with the various blocking agents used. We
found that pre-incubation of the patient samples in blocking reagent reduced this
background.

Samples were incubated with blocking agent for one hour at room

temperature with light rocking prior to addition to the ELISA plate, this incubation
occurred simultaneously to the blocking agent on the ELISA plate. Figure 2.2 shows
the effects of pre-incubation of patient serum with blocking reagent: 5% Donkey Serum
(Equitech-Bio, Kerrville, TX).
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Figure 2.2

Figure 2.2: ELISA: Sample Pre-Incubation with Donkey Serum.
Pre-incubation of 10 patient samples for 1 hour at room temperature with blocking agent (5%
donkey serum) reduced background reactivity. Background is measured on non-coated wells
with only PBS, blocked with donkey serum, and incubated with patient serum followed by
anti-human HRP-conjugated secondary antibody.
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In addition to pre-incubation of each patient sample in blocking reagent, we found
that although proteins were doubly purified using the HIS and T7 tag, we found a few
samples on western blot exhibited non-specific bands.

These bands were not

associated with anti-His tag antibody signal on the IR700 channel, and were detectable
only on the IR800 channel.

On western blot, these non-specific bands were non-

consequential, as quantification was only measure on that IR800 band which
overlapped with IR700 anti-His tag signal.

On ELISA however, these non-specific

reactions create background noise. Pre-adsorption of our patient sample with 75ug/mL
of E. coli bacterial extract reduced non-specific bands observed on western blot as well
as reduced optical density measurement on ELISA.
2.5.1.3.

ELISA Reproducibility

The serum set described in Table 4.1 was processed on ELISA. Each
measurement was run in duplicate per plate, with four plates processed per day over 11
days.

For 88 replicate measurements of the 1:75 dilution of the positive control

standard curve, the coefficients of variation (CV) for the variance components in the
ELISA assay are as follows: Intra-assay CV (within plate) 0.0281; Inter-assay CV (plate
to plate) 0.0749; and CV day-to-day 0.0898 [39]. Reproducibility within a single plate is
shown in Figure 2.3.
2.5.1.4.

Antigen Concentration

Optimal antigen concentration was determined using positive control serum
purchased from The Binding Site (San Diego, CA).

Various lots of these serum

samples were positive for: CDR2, CDR2L, HARS, and TRIM21. For those antigens that
did not have a commercially available positive control serum, we incubated various
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Figure 2.3
A.

B.

Figure 2.3: ELISA Uniform Plate. A. OD values from uniform CDR2-coated ELISA
plate with positive control patient serum as primary antibody. B. OD values from uniform
4F10-coated ELISA plate with anti-HIS tag primary antibody.
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concentrations of antigens with patient serum samples that were previously observed to
react. The concentration of antigen that provided half-maximum signal was selected as
the working antigen concentration for subsequent studies.
2.5.2. ELISA, Validation I
The serum set described in Table 4.1 was processed on ELISA as follows:
purified antigens were coated in duplicate wells at concentrations from 0.3-1.5 mg/mL
(depending on the protein as determine from preliminary tests) in PBS and incubated
overnight at 4°C. All subsequent steps took place at room temperature. Wells were
blocked for one hour with 5% donkey serum in PBS. To eliminate background of patient
sera reactivity with donkey serum and a lysate of nonspecific bacterial proteins,
samples were diluted 1:100 in PBS with 5% donkey serum and 75 mg of BL21-DE3 E.
coli lysate for one hour. Patient samples were incubated on the plate for one hour,
followed by one-hour incubation of donkey anti-human HRP-conjugated secondary
antibody. TMB substrate solution (Thermo Fisher Scientific, Waltham, MA), containing
3.3', 5.5'-tetramethylbenzidine (TMB) was added, followed by 0.45 M sulfuric acid to
stop the reaction after 20 minutes. The addition of blocking solution, washing steps,
TMB and sulfuric acid addition were performed on the Biomek2000 automated liquid
handling robot (Beckman Coulter, Brea, CA).
A standard curve using serum with known reactivity to TRIM21 (The Binding Site,
San Diego CA) at five dilutions ranging from 1:75 to 1:1200 was included on each plate
to account for plate-to-plate and day-to-day variation. In addition, a pair of non-coated
wells were blocked with donkey serum and incubated with each patient serum. These
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patient serum specific background values were subtracted from the antigen values for
each patient sample.
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3. CHAPTER

3:

Selection

of

Antigens

by

Detection

of

Paraneoplastic

Autoantibodies in OVCA sera
3.1. Homology of OVCA Epitopes to Paraneoplastic Antigens
3.1.1. Background: Phage-Display Biopanning
OVCA-related epitopes were previously identified by screening unbiased
random-peptide phage display cDNA libraries using ovarian cancer sera and selectively
enriching reactive epitopes through biopanning with ovarian cancer and healthy control
samples [27, 30].

Using this high throughput epitope cloning strategy, the Tainsky

laboratory identified 56 autoantibody biomarkers for ovarian cancer, three of which
predicted recurrent ovarian cancer 9 months prior to clinical recurrence [27]. One of
these three biomarkers is homologous to paraneoplastic antigen HARS, which is
associated with paraneoplastic myositis [27].

Using NCBI Protein Blast for the 56

sequences reactive with ovarian cancer patient serum, it was found that several
epitopes shared amino acid sequence homology with paraneoplastic antigens [30].
Two epitopes, 4B7 and 3A9, displayed 100% homology to the myositis associated
antigens HARS and SRP-19, respectively [27, 30]. Additionally, four ovarian cancer
epitopes, 4F10, 4E8, 5H6, and 5A3 and showed partial homology to the paraneoplastic
antigens TRIM21, Hu-D, MUSK, and CDR2. Alignments of the epitopes with the fulllength antigen amino acid sequence are shown in Figure 3.1
3.1.2. OVCA epitopes incubated with paraneoplastic IgG on microarray
Commercially available positive control autoimmune serum samples were
purchased from The Binding Site (San Diego, CA). Three control samples were utilized:
positive for the antigens HARS, CDR2, and HU-D (Figure 3.2:A). Although information
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Figure 3.1

Figure 3.1: Homology of OVCA Epitopes to Paraneoplastic Antigens.
Alignments from NCBI protein-BLAST search for OVCA epitopes with proteins associated
with paraneoplastic syndromes. Top sequence indicates OVCA epitope sequence; middle
sequence indicates alignment; bottom sequence indicates full-length protein region of
homology.
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Figure 3.2

Figure 3.2: Autoimmune Patient Serum with OVCA IgG.
A. Overview of positive control serum incubated with OVCA macroarrays.
B. Reactivity of top 4 phage clones reactive with positive control autoimmune serum.
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regarding the disease status of the donor patient was not available, these serum
samples contained high titers of either anti-HARS antibodies, anti-CDR2 antibodies, or
anti-HuD antibodies.

Autoimmune sera were processed with OVCA epitope

macroarrays, with 4 phage clones displaying high reactivity (Figure 3.2:B), confirming
reactivity with both ovarian cancer patient sera and autoimmune condition patient sera.
The 4 reactive phage clones were amplified and purified from E. coli for evaluation on
western blot.
3.2. Paraneoplastic Line Blots
An initial survey of autoantibodies to 20 paraneoplastic antigens in HGSOC sera
[29] [28] was performed, including the five antigens to which ovarian cancer epitopes
showed homology; HARS, SRP-19, TRIM21, CDR2 and Hu-D (Figure 3.3). This study
utilized two commercially available line blots in which recombinant antigens were
spotted onto a membrane, with one line blot test consisting of myositis-associated
antigens, and a second line blot test consisting of onconeuronal antigens associated
with paraneoplastic neurological syndrome.
Myositis-associated antigens were evaluated on line blots from Euroimmun
(EUROIMMUN, Leubeck, Germany) and onconeuronal antigens associated with
paraneoplastic syndromes were evaluated on line blots from Ravo Diagnostika (Ravo
Diagnostika, Freiburg, Germany). The antigens included on the Euroimmun myositis
line blots are: TRIM21, OJ, EJ, PL-12, PL-7, SRP, HARS, PM-SCL75, PM-SCL100, KU,
and MI-2. The antigens included on Ravo Diagnostika paraneoplastic antigen line blots
are: Hu-D, CDR2, RI, CRMP5, AMPHIPHYSIN, MA1, MA2, SOX1, and GAD65. The
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Figure 3.3

Figure 3.3: Paraneoplastic Antigen Line Blots.
Serum set of 34 HGSOC samples, 9 benign samples, and 11 healthy samples processed on
Euroimmun and Ravo Diagnostika line blots, with 20 antigens total.
A: Image of Euroimmun myositis line blot and Ravo Diagnostika paraneoplastic antigen line
blot with anti-HARS and anti-TRIM positive control serum and anti-CDR2 positive control
serum, respectively.
B: Heat map of reactivity of line blots with HGSOC serum, as scored from 0-4.
C: Heat map of reactivity of line blots with benign serum, as scored from 0-4.
D: Heat map of reactivity of line blots with healthy serum, as scored from 0-4.
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line blots were processed per manufacturer protocol, incubated with a serum sample
diluted at 1:100.
3.2.1. Association of Western Blot results with Paraneoplastic Line Blots
There were ten samples processed on both the line blots and on western blot
with the antigens HARS, CDR2, and TRIM21. Results from each platform are shown in
Table 3.1.
3.3. Re-analysis of Recurrence Biomarker Study Data Set
We previously used phage-display screening to identify autoantibody biomarkers
for both early detection and recurrence of ovarian cancer [27, 30]. Two of our identified
markers were epitopes from myositis-associated antigens, HARS and SRP-19. We
note that in our previous work, the antigens CDR2, TRIM21, and HARS were evaluated
for reactivity to antibodies in sera from patients experiencing a recurrence of their
HGSOC; however, in that study the levels of autoantibody were considered relative to a
negative control antigen for each individual patient at three time points, with the goal of
monitoring disease recurrence [28].
With the goal of early detection in the current study, autoantibodies were
considered relative to healthy and benign control serum samples. We re-analyzed data
from the recurrence study establishing a threshold using the healthy control samples
within the sample set. The western blot was quantified as described in section 2.4, with
the anti-Human IgG intensity normalized to the anti-His tag loading control per antigen;
the resulting values are plotted in Figure 3.4. In the original data set, samples were
taken from 3 time points for each patient, labeled as T1, T2, and T3. For this analysis,
we used the second, T2, measurement as it is the time point closest to time of diagnosis
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Table 3.1: Line Blot and Western Blot Association
Reactivity of Antigen
Biomarkers
BSID

Sample ID

CA125

674

P128-Cancer(R)T2

13

1740

P135-Cancer(R)T2

11

1681

P146-Cancer(R)T2

25

3905

P184-Cancer(R)T2

5

3776

P175-Cancer(R)T2

18

784

P25-Cancer(NR)T2

12

832

P164-Cancer(NR)T2

28

4012

P189-Cancer(NR)T2

6

4069

P206-Cancer(NR)T2

7

7428

P281-Cancer(NR)T2

6

Test

HARS

Western Blot

0.1

TRIM21

CDR2
0.21

Line Blot
Western Blot

15.15

1.75

Line Blot

3

4

Western Blot

0.09

Line Blot

0.45
1

Western Blot

0.2

Line Blot

2

Western Blot

34.5

Line Blot

4

Western Blot

0.3

0.1

Line Blot
Western Blot
Line Blot
Western Blot

0.07

Line Blot

1.93

0.29

2

1

Western Blot
Line Blot

1

Western Blot

0.06

Line Blot

1

1

Table 3.1: Reactivity of 10 samples evaluated on line blot and western blot with TRIM21,
HARS, and CDR2 antigens.

58
Figure 3.4

Figure 3.4: TRIM Reactivity and CA125. A. Western blot reactivity with TRIM21. B.
Western blot reactivity with TRIM21 with HGSOC cases grouped by CA125 status.
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before treatment and most closely matches the serum samples used in our early
detection studies. 10/31 (32%) HGSOC ovarian cancer cases were positive for TRIM21
protein, with 0/21 healthy control samples, and 1/22 (0.05%) of samples from women
with benign gynecological conditions, shown in Figure 3.4.

Figure 3.4:B shows

samples that had CA125 values below clinical cutoff.
3.4. Western blot and ELISA preliminary screening
Next, selected antigens were purified for further analysis on western blot and
ELISA. The following antigens were either expressed in E. coli and purified in house, or
obtained commercially for quantitation in western blot and ELISA assays: SRP-19,
HARS, AARS, CDR2, HuD, TRIM21, TRIM33, CDR2L, CORTACTIN, CKB, NY-ESO-1,
PAX8 and TP53 (Table 3.2). In addition, the four phage display epitopes with homology
to paraneoplastic antigens were sub-cloned, expressed in E. coli and purified [27]. A
representative western blot is shown in Figure 3.5. Both the homologous epitopes and
full-length protein pairs were evaluated; in all cases the full-length protein provided
increased sensitivity.

Therefore the full-length protein was utilized in future studies

rather than the purified epitope peptides.
The serum set of n=36 samples is described in Table 3.3 and consisted of 12
Healthy control samples, 12 samples representing benign gynecologic conditions
including uterine fibroids, endometriosis, and ovarian cysts, and 12 late-stage HGSOC.
Western blot was performed first with 11 antigens. HARS, TRIM21, CDR2, and P3F10
had the lowest individual one-way ANOVA p-values. Individual antigen reactivity is
shown in a matrix plot in Figure 3.6. Each purified antigen was incubated with patient
sera autoantibodies, followed by incubation with secondary antibody to human IgG, and
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Table 3.2: Description of Paraneoplastic Antigens Evaluated Against HGSOC Sera.

Category

Myositis

PCD

Other
PNS

Antigens
purified for
western
blot/ELISA
screening

Epitope purified
for western
blot/ELISA
screening

Autoantibodies
targeting antigens

Autoimmune
conditions
associated with
Autoantibodies

Cancers types
associated with
Autoantibodies

Reference

HARS

4B7: Epitope

Jo-1

Myositis,
Dermatomyositis

OVCA, lung

[180, 203]

TRIM21

4F10: Epitope

Ro-52

Myositis, Systemic
lupus erythematosus,
Sjogren's Syndrome

ECC, Basal-like
breast cancer

[100, 185]

Anti-SRP-19

Myositis

Breast,
endometrial,
hepatocellular,
bladder

[3, 180]

CORTACTIN

Anti-Cor

Myositis

AlaRS

PL-12

Myositis

Lung, gastric

[180, 197]

TRIM33

Anti-TIF1-γ

Myositis

Lung, breast,
OVCA,
stomach

[117, 180,
203]

CDR2

Yo

Breast, OVCA

[52, 124]

CDR2L

Yo

Breast, OVCA

[52, 98]

CKB

Anti-CKB

OVCA

[174]

SCLC

[93, 137]

SRP-19

HuD

4E8: Epitope

Anti-Hu

Paraneoplastic
Cerebellar
Degeneration
Paraneoplastic
Cerebellar
Degeneration
Paraneoplastic
Cerebellar
Degeneration
Encephalomyopathy,
sensory
neuronopathy

[102]

Anti-P3F10

OVCA epitope that
binds PNS sera

OVCA

[27]

TP53

Anti-TP53

Systemic lupus
erythematosus,
Type I Diabetes, AI
Thyroid Disease

Pancreatic,
Breast, OVCA

[31, 91]

NY-ESO-1

Anti-NY-ESO-1

N/A, Cancer/Testis
Antigen

Lung, Breast,
OVCA

[175]

PAX8

Anti-PAX8

N/A

Antigen
overexpression
in OVCA

[189]

P3F10

TAA

3A9: Epitope

Table 3.2: Paraneoplastic antigens purified; the 8 antigens shaded in gray are those selected for
the large-scale screening on western blot and ELISA. Epitopes identified by phage-display
screening of ovarian cancer (OVCA) serum [27]. PNS=Paraneoplastic Neurological Syndrome,
PCD=Paraneoplastic Cerebellar Degeneration, TAA=Tumor Associated Antigen.
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Figure 3.5

Figure 3.5: Western Blot Image, n=36.
Purified antigens on western blot. Blue boxes indicate full-length protein and corresponding
homologous OVCA epitope pair. A. anti-HIS tag antibody. B. Patient serum and antiHuman IgG.
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Table 3.3: Serum sample patient population (n=36), analyzed on western blot and
ELISA, preliminary screening.
Preliminary Screening Set
Number of
Patient Description
Samples
Late Stage HGSOC at time of
12
diagnosis, pre-treatment
Benign gynecological condition
12
(ovarian cyst, endometriosis, uterine fibroids)
Healthy volunteers from community
12
outreach

Age range
(Avg)(Median)
44-47
(57.4) (56.5)
29-72
(50.1) (50.5)
51-77
(63.6) (64.5)

Table 3.3: Patient Population, n=36. Serum samples analyzed on ELISA and western blot.
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Figure 3.6

Figure 3.6: Matrix Plot, n=36
Ratio of IR800:IR700 value representing the anti-Human IgG antibody adjusted for protein
loading with the anti-HIS tag antibody is plotted on the X and Y axes for each possible
marker pair as labeled in the center diagonal gray boxes, with each patient sample represented
as a single point. Benign samples are labeled in blue, cancer samples are labled in red, and
healthy samples are labled in green. Red boxes represent the pairs which individually
significantly separate cancer from healthy and benign by one-way ANOVA.
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to 6X Histidine tag. Anti-human antibody intensity is normalized to antibody intensity for
each his-tagged antigen.

As a visual representation of which marker pairs were

compatible, each antigen pair was plotted against the other using a matrix plot in a log
scale so that each patient could be represented by a single point defined by two
markers, which are labeled as cancer, healthy, or benign in Figure 3.6. Certain
combinations separated the cancer category to the upper quadrant, so additive effects
of marker pairs were then evaluated.

Combining the four markers HARS, P3F10,

TRIM21, and CDR2 by taking the log of the product (equal to the sum of the four marker
values on a log scale), the p-values using one-way ANOVA are: 4.9E-06 for Healthy vs.
HGSOC and 1.2E-05 for Benign vs. HGSOC.
This set of 36 serum samples was also run on ELISA, 3 times, each time
adjusting ELISA conditions. Differences in antigen concentration are shown in Table
3.4. Additionally, the number of plates processed per day and the order in which they
were processed varied between studies, as we found that variation in plate drying time
between washing steps affected results as observed by an order-processed effect. The
ELISA procedure established in the third ELISA experiment with the n=36 sample set
are the conditions utilized in the large-scale n=164 experiment as described in section
2.5.2.
Results from western blot and ELISA screening with a serum set of n=36
samples are shown in Table 3.4. This set of 12, 12, 12 samples was also included in
the study of recurrent ovarian cancer described in section 3.1, utilizing the T2 time
points as described in section 3.2. This represents western blot 2 as labeled WB2 in
Table 3.4.
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Table 3.4: Results from Preliminary Screening of Purified Recombinant Proteins on
Western Blot and ELISA.

Table 3.4: Positive Samples from 3 ELISA and 2 western blot screening, performed with
varying antigen concentrations as shown. A set of 36 sera consisting of 12 healthy, 12 benign
gynecological disease, and 12 high-grade serous ovarian cancer was run on three separate
ELISA experiments, as well as twice on western blot. Sensitivity is calculated relative to
healthy and benign samples at 90% specificity. With these six markers, a total of 10/12
samples were positive using at least one assay. Samples positive for each assay are shaded in
gray per antigen.
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3.5. Description of Antigens Selected for Large-Scale Validation (n=164)
From the commercial line blot, western blot, and ELISA screenings, three
myositis-associated antigens, three paraneoplastic cerebellar degeneration associated
antigens, and three tumor-associated antigens were selected for validation on a largescale western blot and ELISA study using an independent sample set. The 8 selected
antigens are highlighted in Table 2.1.
HARS, Histidyl-tRNA synthetase.
HARS catalyzes the transfer of Histidine to its cognate tRNA during protein
synthesis, and HARS splice variants have reported immuno-modulatory roles [210].
Antibodies against the HARS antigen are termed Jo-1 autoantibodies [193, 203]. AntitRNA synthetase antibodies are common in myositis, with Jo-1 autoantibodies having
the highest frequency [35].
TRIM21, E3 ubiquitin-protein ligase TRIM21, Sjogren’s Syndrome type A antigen.
TRIM21 has E3-ligase activity as well as roles in intracellular pathogen clearance
with a potent fc-receptor and activation of the innate immune response [121].
Antibodies against TRIM21 are termed SSA-autoantibodies or Ro-52 autoantibodies
and are associated with Sjogren’s syndrome, myositis, systemic lupus erythematosis,
and systemic sclerosis [133, 134] .
Cortactin, Src substrate cortactin.
Anti-cortactin autoantibodies were identified in sera of patients with polymyositis
and in a separate study in myasthenia gravis who were sero-negative for classic
paraneoplastic

antigens

[18].

Cortactin

expression

as

measured

by
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immunohistochemistry and mRNA analysis of tumor tissues was reported to be
associated with poor prognosis in ovarian cancer [108].
CDR2, Cerebellar degeneration-related protein 2.
CDR2 interacts with c-myc and down-regulates c-myc dependent transcription in
tumor cells, and is involved in mitotic cell division [130, 171]. Autoantibodies against the
CDR2 antigen are termed Yo autoantibodies and are detected in patients with
paraneoplastic cerebellar degeneration [46, 52].
CDR2L, Cerebellar degeneration related protein 2-like.
CDR2L (CDR2-Like) shares 50% homology to CDR2; Yo autoantibodies can
target both proteins. The function of CDR2L is unknown [52].
TP53, Cellular tumor antigen p53.
TP53 is a tumor suppressor and transcription factor involved in cell cycle
regulation, DNA repair activation, apoptosis activation, and senescence.

Somatic

mutations in p53 are found in approximately half of all human cancers, and in 96% of
HGSOC cases [37]; autoantibodies to p53 in HGSOC can be detected against the wild
type protein as a polyclonal response [91]. Autoantibodies to p53 are also detected in
autoimmune conditions in which DNA antibodies are present, such as SLE, type I
diabetes, and autoimmune thyroid disease [31].
NY-ESO-1, Cancer/testis antigen 1.
NY-ESO-1 is involved in cell growth and apoptosis. The restricted expression in
testis suggests germ cell self-renewal function. Anti-NY-ESO-1 autoantibodies,
originally identified by SEREX technology, have been detected in multiple tumor types
including ovarian, breast, lung, and melanoma [33]. NY-ESO-1 is an immunotherapy
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target for ovarian cancer with numerous trials evaluating vaccines targeting NY-ESO-1
as well as adoptive transfer of NY-ESO-1 specific T-cells [13, 131].
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4. CHAPTER 4: Validation I: 14 Antigens Screened with n=164 Serum Sample Set
on ELISA and Western Blot
4.1. Patient Sample Population, n=164, Processed on ELISA and Western Blot
To avoid experimental bias, an independent sample set of 164 samples that had
not been used to identify the biomarkers initially was used for validation of the antigens
described in chapter 3.

The sample population consisting of 50 healthy control

samples, 50 benign ovarian cyst samples, 50 late stage HGSOC samples, and 14 early
stage HGSOC samples is described in Table 4.1, and will be referred to as the
Validation I sample set.
4.2. 12 Antigens Evaluated on ELISA or Western Blot with n=164 Sera
4.2.1. Methods: ELISA
4.2.1.1.

Antigens

The following 8 antigens were screened on ELISA: TRIM21, HARS, CDR2,
CDR2L, NYESO1, TP53, and P3F10 using T712A as a negative control. P3F10 was an
epitope selected in chapter 3 based on elevated reactivity with sera from patients with
paraneoplastic syndromes. The empty phage control T712A was included as P3F10
epitope includes a portion of this phage coat sequence. The reactivity of P3F10 was
determined by subtracting the T712A OD value from the P3F10 OD value. TRIM21 and
HARS are antigens associated with myositis/dermatomyositis, CDR2 and CDR2L are
associated with paraneoplastic cerebellar degeneration, and TP53 and NY-ESO-1 are
tumor-associated antigens previously demonstrated to react with autoantibodies in
ovarian cancer serum [6, 173].
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Table 4.1: Serum Sample Patient Population (n=164), Analyzed on Western Blot and
ELISA, Validation I.

Validation Set I
Number of
Patient Description
Samples
Late Stage HGSOC at time of
50
diagnosis, pre-treatment
Early Stage HGSOC at time of
14
diagnosis, pre-treatment
Benign gynecological condition
50
(ovarian cyst)
Healthy volunteers from community
50
outreach

Age range
(Avg)(Median)
39-81*
(62.6) (62)
44-76
(58.8) (57)
17-76
(48.8) (49.5)
32-88
(56.2) (53)

Table 4.1: Patient Population, n=164. Serum samples analyzed on ELISA and western blot.
*Indicates age not available for 3 cases.
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4.2.1.2.

Standardization

For the ELISA data analysis, to adjust for day-to-day variability among the 44
ELISA plates measured across 11 days, we utilized the positive control measurements
to construct the standard curve, which was measured on all plates. The linear curve
consisted of 6 dilutions of a positive control serum sample (The Binding Site, San
Diego, CA) measured against TRIM21 in duplicate, as shown in Figure 4.1. A linear
mixed model with log optical density (OD) as the response; dilution (treated as a factor),
protein (either TRIM21 or BKG) and their interaction as the fixed effects; plate nested
within day as a random effect; an estimated correlation structure between duplicate
observations; and unequal variance within each protein/dilution combination. From this
model, we extracted the random effects terms to adjust the observed log(OD) values.
After averaging the duplicates and exponenting resultant value, the appropriate control
adjusted OD was subtracted to produce the normalized OD measurement. This
normalized OD measurement was then used to compare to the values from the western
blot analysis.
4.2.2. Methods: Western Blot
4.2.2.1.

Antigens

The following 10 antigens were evaluated on western blot:

TRIM21, HARS,

CDR2, CORTACTIN, CDR2L, NYESO1, TP53, BRCA-1, CMYC, and PAX8. TRIM21,
HARS, and CORTACTIN are antigens associated with myositis/dermatomyositis, CDR2
and CDR2L are associated with paraneoplastic cerebellar degeneration, and TP53, NYESO-1, BRCA-1, CMYC, and PAX-8 are tumor-associated antigens previously
demonstrated to react with autoantibodies in ovarian cancer serum or are over-
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Figure 4.1

Figure 4.1: ELISA Standard Curve, Validation I, n=164
The ELISA assay was run with a standard curve of 0.75 µg TRIM21 incubated with 5
dilutions (1:1200, 1:600, 1:300, 1:150, 1:75) of the same positive control patient serum per
plate. This curve was used to adjust sample values for day-to-day variation. Each color
represents one day, each data point represents the average of two duplicate backgroundcorrected measurements per plate, with 4 plates processed per day.
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expressed in HGSOC. These 10 antigens were processed on two separate western
blot studies; the first study included the 7 antigens TRIM21, HARS, CDR2,
CORTACTIN, CDR2L, NYESO1, TP53, and the second study included the 3 antigens
BRCA-1, CMYC, and PAX8. Figure 4.2 shows the first set of 7 antigens on western
blot with the Validation I sample set.
4.2.2.2.

Standardization

Quantification of autoantibody binding on western blot for each sample was
measured over 15 days for Validation I for each of the 8 antigens, and measured over
16 days for Validation II for 4 antigens, utilizing multiple membranes per day. Samples
were randomized per category of HGSOC, benign, and healthy with each category
evenly distributed per day, and labeled so that the experimenters were blinded to the
sample category. The quantification values for both the IRDye700 and IRDye800
channels were log transformed after the addition of a small constant (0.01) to ensure all
values were positive. The difference between the log transformed IRDye700 and
IRDye800 values for each antigen for each sample is the pre-adjustment analysis
metric. We employed a mixed model to develop adjustment factors to account for the
between-day variability. We utilized the estimated day-specific random effects (from a
model including the log difference as the response, antigen as the fixed effect and day
as the random effect) to account for day-to-day variability. The log difference minus the
day-specific random effect was used as the final analysis metric. Subsequently, for
each antigen, the mean and standard deviation of the analysis metric was computed
using the healthy samples. This standardized value was used in the figures and tables
presented in this manuscript.

Methods: Western Blot
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Figure 4.2

Figure 4.2: Western Blot Image, Validation I, n=164.
Western blot of healthy control serum and early stage HGSOC serum diluted at 1:300 with 7
antigens in Validation I study. A) Secondary antibody anti-HIS tag IgG loading control. B)
Secondary antibody anti-human IgG. Scans quantified on Odyssey software; backgroundcorrected integrated intensity of anti-human IgG antibody (IRDye800) normalized as ratio to
anti-His tag antibody (IRDye700) per antigen.
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4.2.3. Results
4.2.3.1. Individual Antigen Results: ELISA
Individual antigen reactivity is shown in Figure 4.3. Positive control serum for
HARS, TRIM21, and CDR2 as described in section 3.1.2 were also evaluated on
ELISA.
4.2.3.2.

ELISA Saturated Signal

Samples that generated a saturated signal on ELISA were assigned a maximum
OD value of 4 for analysis. All samples with saturated signal were confirmed as positive
on western blot (Figure 4.4).
4.2.3.3.

Individual Antigen Results: Western Blot

The ratio of anti-human IgG:anti-HIS IgG intensity values are plotted for each
antigen for the late-stage HGSOC, early-stage HGSOC, benign ovarian cyst, and
healthy control groups in Figure 4.5.
4.2.3.4.

ELISA and Western Blot Correlation

A threshold based on the 50 healthy control values for each antigen defined
positive results.

The assay cutoff for both the ELISA assay and the western blot

screening is defined as: Mean + 2(StdDev) for the healthy controls. Using this criterion,
NY-ESO-1, TP53, and TRIM21 had the highest sensivities and specificities on both
platforms. Among all HGSOC samples (n=64), 16/18 samples positive for NY-ESO-1
on ELISA were confirmed by western blot, 14/16 TP53 samples positive on ELISA were
confirmed by western blot and 11/13 TRIM21 samples positive on ELISA were
confirmed by western blot. However, for the marker TRIM21, 10 additional positive
samples were identified on western blot that were not detected by ELISA.
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Figure 4.3

Figure 4.3: ELISA Individual Antigen Graphs, Validation I, n=164. Background-adjusted
normalized optical density for each antigen. H=healthy, M=mucinous cyst, S=serous cyst,
E=early stage HGSOC, S3=stage 3 HGSOC, S4=stage 4 HGSOC, BX=positive control serum
(The Binding Site, San Diego, CA).
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Figure 4.4

Figure 4.4: Samples with ELISA Saturated Signals Confirmed on Western Blot.
ELISA saturated signals for TP53 and TRIM21 confirmed as specific positive reactions on
western blot. IR800 anti-human IgG is shown in green, IR700 anti-HIS antibody is shown in
red, overlap is shown in yellow.

Figure 4.5
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Figure 4.5: Western Blot
Individual Antigen Reactivity,
Validation I, n=164.
H=Healthy, M=Mucinous Cyst,
S=Serous Cyst, E=Early stage
HGSOC, S3=Stage 3 HGSOC,
S4=Stage 4 HGSOC

nnnnnnn

79

Figure 4.6

Figure 4.6: Correlation of Western Blot and ELISA. NY-ESO-1, TP53, and TRIM21
western blot values correlated with ELISA values; each sample is represented as a single data
point. Red represents HGSOC cases, black indicates healthy or benign cases. Samples in the
upper right quadrant were positive on both ELISA and western blot.
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4.2.3.5.

ELISA Treatment with Reducing Agent DTT

Prior studies have demonstrated enhanced detection of anti-TRIM21 antibodies
on ELISA under reducing conditions, including samples with autoantibodies that were
undetectable in non-reducing conditions [134, 141]. In Validation I, a threshold based
on the 50 healthy control values for each antigen defined positive results. Seven of the
positive samples that were identified on western blot but were not detected by ELISA
were processed again on ELISA using TRIM21-coated plates that were treated with
DTT.

Results are shown in

Table 4.2; treatment with DTT did not affect ELISA

reactivity. A representative image of a sample positive for TRIM21 on western blot that
was undetectable by ELISA is shown in Figure 4.7. Additionally, the marker HARS did
not react on ELISA whereas it showed reactivity on western blot. HARS was treated
with DTT, and did not show any improvement in ELSA detection for 2 samples that were
positive on western blot.
Lack of reactivity can be due to protein binding to the plate and resulting epitope
availability on ELISA, as well as increased background noise in the ELISA platform that
can interfere with detection of a positive signal. A number of patient samples retained
an inherent high background on ELISA regardless of pre-incubation of the serum
sample with blocking agent (5% donkey serum) and bacterial extract as described in
Methods.

It was concluded that western blot eliminates ambiguities introduced by

samples with high background noise and is the more reliable platform for detection of
patient autoantibodies. Therefore, subsequent analyses employed western blot data.
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Table 4.2 ELISA Results: TRIM21 + DTT

N=164
Protein Sample #
ID

TRIM21
Status,
n=164
study

TRIM21
ELISA
ELISA
Status,
ABS-BKG ABS-BKG
n=164 study NO DTT
+ DTT

Delta
(NO
DTT) (+DTT)

TRIM21 Sample 1

O47

WB +

ELISA -

0.409

0.369

0.041

TRIM21 Sample 2

O40

WB +

ELISA -

0.254

0.275

-0.022

TRIM21 Sample 3

O12

WB +

ELISA -

0.209

0.216

-0.007

TRIM21 Sample 4

O46

WB +

ELISA -

0.305

0.211

0.094

TRIM21 Sample 5

O33

WB +

ELISA -

0.134

0.127

0.007

TRIM21 Sample 6

O3

WB +

ELISA -

0.012

-0.014

0.026

TRIM21 Sample 7

O37

WB +

ELISA +

1.940

1.956

-0.017

TRIM21 Sample 8

O38

WB -

ELISA -

0.042

0.067

-0.025

TRIM21 Sample 9

O42

WB -

ELISA -

-0.014

-0.05

0.036

Table 4.2: Treatment with reducing agent DTT on ELISA. OVCA samples positive on WB
and not on ELISA. Addition of DTT had no affect on ELISA sample reactivity.
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Figure 4.7

Figure 4.7: Western Blot of Late-Stage HGSOC Sample Positive for TRIM21,
Validation I.
Late-Stage HGSOC sample positive for TRIM21 (800:700 standardized ratio > 2) on western
blot, which was not detected by ELISA (Standardized background-corrected intensity <2).
A) Secondary antibody anti-HIS tag IgG loading control. B) Secondary antibody anti-human
IgG.
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4.2.3.6. Sensitivity/Specificity: TRIM21 provides highest sensitivity as
an individual marker in HGSOC samples.
Sensitivities and specificities as calculated by the standardized thresholds based
on mean + 2(StdDev) of the healthy controls and mean + 3(StdDev) of the healthy
controls per antigen are reported in Table 4.3. The resulting thresholds were applied to
all patient groups: healthy, benign, early stage HGSOC, and late stage HGSOC.
Applying the assay threshold=2 for western blot to TRIM21 yields 21 positive samples
out of 64 HGSOC cases, including both early and late stage.

Notably, with 33%

sensitivity TRIM21 did not positively react with healthy control samples. Four benign
ovarian cyst samples had reactivity above the healthy control threshold.

Individual

sensitivities and specificities of all markers are shown in Table 4.3; the previously
established biomarkers NY-ESO-1 and TP53 each detected 16/64 (25%) of HGSOC
cases. One healthy control sample with high reactivity to TP53 had self-reported family
history of ovarian cancer.
Cortactin (COR), a novel biomarker for myositis, did not show HGSOC specificity
[102].

We found that CDR2 and CDR2L had reactivity with healthy and benign

samples. Antibodies to CDR2 have previously been reported to have low frequency in
ovarian cancer. We observed 5/50 late stage and 2/14 early stage samples positive for
CDR2 autoantibodies at the threshold (2)=Mean + 2(StdDev) [124]. Previous studies
have shown that Yo-antibody positive patients with paraneoplastic cerebellar
degeneration have anti-Yo antibodies that react with both CDR2 and CDR2L [52]. In a
study evaluating ovarian cancer sera, anti-Yo positive sera reacted with CDR2L alone,
or both CDR2 and CDR2L [52]. In our cohort, the three samples that were positive for
both CDR2 and CDR2L were late-stage serous ovarian cancer cases (Table 4.4).
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Table 4.3 Sensitivity/Specificity for Validation I.
Late and
Early
Stage
HGSOC
(n=64)

Positive Threshold=2

Late Stage
HGSOC
(n=50)

Early
Stage
HGSOC
(n=14)

Antigen

Sensitivity

Sensitivity

TRIM21
TP53
NYESO1
HARS
CDR2L
CDR2
COR
TRIM21, TP53, NYESO1

0.34
0.28
0.24
0.06
0.06
0.10
0.02
0.64

0.29
0.14
0.29
0.29
0.14
0.14
0.00
0.43

0.33
0.25
0.25
0.11
0.08
0.11
0.02
0.59

Positive Threshold=3

Late Stage
HGSOC
(n=50)

Early
Stage
HGSOC
(n=14)

Late and
Early
Stage
HGSOC
(n=64)

Antigen

Sensitivity

Sensitivity

TRIM21
TP53
NYESO1
HARS
CDR2L
CDR2
COR
TRIM21, TP53, NYESO1

0.28
0.26
0.22
0.02
0.02
0.06
0.02
0.58

0.21
0.14
0.29
0.21
0.14
0.14
0.00
0.36

Healthy
(n=50)

Benign
and
Healthy
(n=100)

Specificity

Specificity

0.90
0.98
0.98
0.90
0.94
0.88
1.00
0.86

1.00
0.96
0.98
0.98
0.96
0.96
0.96
0.94

0.95
0.97
0.98
0.94
0.95
0.92
0.98
0.90

Benign
(n=50)

Healthy
(n=50)

Benign
and
Healthy
(n=100)

Specificity

Specificity

1.00
0.98
1.00
1.00
1.00
0.98
0.96
0.98

0.96
0.99
1.00
0.99
0.98
0.96
0.98
0.96

Benign
(n=50)

Sensitivity Specificity

Sensitivity Specificity

0.27
0.23
0.23
0.06
0.05
0.08
0.02
0.53

0.92
1.00
1.00
0.98
0.96
0.94
1.00
0.94

Table 4.3: Sensitivity and specificity for TRIM21, TP53, NY-ESO-1, HARS, CDR2L,
CDR2, and COR evaluated on western blot with n=164 sample set. Threshold (2)=Mean +
2(StdDev) for healthy controls, threshold (3)=Mean + 3(StdDev) for healthy controls.
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Table 4.4 CDR2 and CDR2L Combined Reactivity, n=164, Validation I

Antigen

Benign
(n=50)

Healthy
(n=50)

All
HGSOC
(n=64)

Early
Stage
(n=14)

Late
Stage
(n=50)

CDR2>2

6

2

7

2

5

CDR2L>2

3

2

4

1

3

CDR2>2 +
CDR2L>2

0

0

3

1

2

Antigen

Benign
(n=50)

Healthy
(n=50)

All
HGSOC
(n=64)

Early
Stage
(n=14)

Late
Stage
(n=50)

CDR2>2

6

2

7

2

5

CDR2L>1.5

6

3

6

2

4

CDR2>2 +
CDR2L>1.5

0

0

4

2

2

Table 4.4: CDR2 and CDR2L, n=164, Validation I. Samples positive for both CDR2 and
CDR2L were all HGSOC cases. Thresholds of 1.5 or 2 shown for individual antigens or the
combination of CDR2 and CDR2L.
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In cases of myositis, patients that had the combination of TRIM21 and HARS were
more likely to have cancer [115, 149]. In our cohort we observed 3/64 HGSOC patients
with a combination of HARS and TRIM21 positive values.
4.3. Additional Ovarian Cancer Tumor-Associated Antigens screened with
n=164 sample set on western blot: BRCA1, CMYC, PAX8
4.3.1. Study Design
Three additional tumor-associated antigens were evaluated with the Validation I sample
set: BRCA1, CMYC, and PAX8.
4.3.1.1.

Antigen Description

C-myc, C-myc protein.
In a study by Wang et. al evaluating 12 tumor-associated antigens to identify
ovarian cancer biomarkers, C-myc was identified as a top candidate biomarker as
measured by ELISA. C-myc was detected in 24/132 (18.2%) of ovarian cancer serum
samples, and 3/147 (2%) of healthy control samples, with the positive cutoff defined as
mean + 2 standard deviations of the healthy control samples [186].
BRCA1, Breast cancer type I susceptibility protein.
Autoantibodies to BRCA1 were detected in 17/34 ovarian cancer samples on
ELISA [211].

BRCA1 and BRCA2 mutations account for the majority of hereditary

breast and ovarian cancer cases [136].
PAX8, Paired box protein Pax-8.
Overexpression of PAX8 is associated with HGSOC [20, 189].

The present

study is the first to detect anti-PAX8 autoantibodies. The full-length PAX8 protein is 450
aa; the recombinant PAX8 protein used in this study consists of the amino acids 1-287,
which are present on isoforms C-E.
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4.3.2. Results
Western blot image of patient serum with the three antigens CMYC, BRCA1, and
PAX8 is shown in Figure 4.8. Individual antigen reactivity is shown in Figure 4.9. Of
the three markers, PAX8 demonstrated potential to complement NY-ESO-1, TP53, and
TRIM21. Alone, PAX8 was positive for 7/64 HGSOC samples, 5 of which were not
detected previously. Although previously reported to be elevated in HGSOC patient
serum, both BRCA1 and CMYC reacted with HGSOC, healthy control, and benign
ovarian cyst samples on western blot (Figure 4.9) [186, 211].
4.4. Analysis of 10 antigens Screened with n=164 Sera on Western Blot
Identifies Top Panel of 4 Antigens: TRIM21, NY-ESO-1, TP53, and PAX8
4.4.1. Panel of 4 Antigens: TRIM21, NY-ESO-1, TP53, and PAX8 provides
highest sensitivity and specificity.
The combination of the four markers TRIM21, NY-ESO-1, TP53, and PAX8
detected 42/64 HGSOC samples.

With 94% specificity for the healthy control

population, we can achieve 67% sensitivity (threshold=2) for the 4-marker model. At
98% specificity relative to the healthy control population, this 4-marker combination
achieves 56% sensitivity (threshold=3). The maximum value among the 4 markers:
TRIM21, NY-ESO-1, TP53, and PAX8 for each sample group is plotted in Figure 4.10.
Table 4.5 shows performance of the combinations of these 4 markers. ROC Curve
analysis of the 4-marker panel is shown in Figure 4.11.
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Figure 4.8

Figure 4.8: Western Blot Images, n=164, Validation I, Additional Tumor-Associated
Antigens. BRCA1, PAX8, and CMYC proteins with anti-HIS tag antibody shown on left
panel. Healthy, HGSOC, and Benign patient samples with anti-Human IgG antibody shown
on right panel. Reactivity of BRCA1 and CMYC is observed in Healthy and Benign
samples.
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Figure 4.9

Figure 4.9: Western Blot Individual Antigen Reactivity, n=164, Validation I, Additional
Tumor-Associated Antigens. H=Healthy, B=Benign, E=Early Stage HGSOC, O=Late
Stage HGSOC. BRCA1 and CMYC react with all sample types.
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Figure 4.10

Figure 4.10: Western Blot Individual Antigen Reactivity, 4 Antigens, Validation I,
n=164.
A-D) Individual antigen plots for 4 antigens, TRIM21, NY-ESO-1, TP53, and PAX8 in
Validation I. E) Maximum value of TRIM21, NY-ESO-1, TP53, or PAX8 in Validation I.
The immunoreactivity as defined by the ratio of 800/700 is standardized for each antigen to
provide the threshold of Mean + 2(StdDev) for healthy controls, as indicated by the
horizontal line at Y=2.
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Figure 4.11

Figure 4.11: ROC Curve Analysis, Validation I, n=164.
ROC curve analysis for the combination of the 4 markers: TRIM21, NY-ESO-1, TP53, and
PAX8 in Validation I
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4.4.2. TRIM21, HARS, NY-ESO-1, PAX8, and TP53 detected in early stage
HGSOC samples.
The Validation I sample set included 14 early stage samples. Individually, NYESO-1 and HARS detected 4 early-stage HGSOC samples (29%), TRIM21 detected 3
early-stage HGSOC samples (21%), and TP53 and PAX8 each detected 2 early-stage
HGSOC samples (14%). The combination of the 5 markers yielded 50% sensitivity for
detecting early stage HGSOC with 94% specificity to discriminate healthy controls.
Sensitivities and specificities within each sample group are shown in Table 4.5. The
combination of markers PAX8, HARS, NY-ESO-1, TP53 and TRIM21 detected 7/14
early-stage HGSOC samples. Among these five antigens, all 7/7 of the positive early
stage HGSOC samples were reactive with 2 or more antigens, compared with 12/37
positive late stage HGSOC samples reacting with 2 or more antigens.

93
Table 4.5 Sensitivity/Specificity for TRIM21, NY-ESO-1, TP53, and PAX8, Validation I.
Late and
Early
Stage
HGSOC
(n=64)

Positive Threshold=2

Late Stage
HGSOC
(n=50)

Early
Stage
HGSOC
(n=14)

Healthy
(n=50)

Benign
and
Healthy
(n=100)

Antigen

Sensitivity

Sensitivity

Specificity

Specificity

TRIM21
TP53
NYESO1
PAX8
TRIM21, TP53, NYESO1
TRIM21, TP53,
NYESO1, PAX8

0.34
0.28
0.24
0.10
0.64

0.29
0.14
0.29
0.14
0.43

0.33
0.25
0.25
0.11
0.59

0.90
0.98
0.98
0.96
0.86

1.00
0.96
0.98
1.00
0.94

0.95
0.97
0.98
0.98
0.90

0.72

0.50

0.67

0.82

0.94

0.88

Positive Threshold=3

Late Stage
HGSOC
(n=50)

Early
Stage
HGSOC
(n=14)

Late and
Early
Stage
HGSOC
(n=64)

Benign
(n=50)

Healthy
(n=50)

Benign
and
Healthy
(n=100)

Antigen

Sensitivity

Sensitivity

Specificity

Specificity

TRIM21
TP53
NYESO1
PAX8
TRIM21, TP53, NYESO1
TRIM21, TP53,
NYESO1, PAX8

0.28
0.26
0.22
0.04
0.58

0.21
0.14
0.29
0.00
0.36

0.27
0.23
0.23
0.03
0.53

0.92
1.00
1.00
0.96
0.94

1.00
0.98
1.00
1.00
0.98

0.96
0.99
1
0.98
0.96

0.62

0.36

0.56

0.88

0.98

0.93

Benign
(n=50)

Sensitivity Specificity

Sensitivity Specificity

Table 4.5: Sensitivity and specificity for TRIM21, NY-ESO-1, TP53, and PAX8 evaluated
on western blot with n=164 sample set. Threshold (2)=Mean + 2(StdDev) for healthy
controls, threshold (3)=Mean + 3(StdDev) for healthy controls.
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5. CHAPTER 5: Validation II: Study of 4 Antigens on western blot
A separate serum set consisting of 50 healthy, 50 benign ovarian cyst, and 50
high-grade serous ovarian cancer samples was used for an independent validation of
the 4 markers: TRIM21, NY-ESO-1, TP53, and PAX8. This sample set will be referred
to as Validation II.
5.1.1. Patient population, n=150
The patient population is described in Table 5.1.
5.1.2. Antigens
Antigens were selected based on performance in Validation I for detection of
HGSOC autoantibodies.

The four markers TRIM21, NY-ESO-1, TP53, and PAX8

achieved the greatest AUC relative to healthy control samples in Validation I.
5.2. Results
5.2.1. Individual Antigen Results
Patient samples were evaluated with the panel of 4 markers: TRIM21, NY-ESO1, TP53, and PAX8 on western blot (Figure 5.1). In this sample set, PAX8 did not
complement the 3 markers TRIM21, NY-ESO-1, and TP53.

Standardized patient

reactivity for each antigen is shown in Figure 5.2. This validation screening of the 3
markers TRIM21, NY-ESO-1, and TP53 maintained a specificity of 98% with a
sensitivity of 46% as described in Table 5.2.
5.2.2. Comparison to Validation I Study
The sensitivity of the combination of the 4 markers: TRIM21, NY-ESO-1, TP53,
and PAX8 for all HGSOC cases was lower in the second validation study, 50% vs. 67%
with positive threshold=2, and 46% vs. 56% with positive threshold=3. This difference is
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Table 5.1: Serum sample patient population (n=150), analyzed on western blot,
Validation II.

Validation Set II
Number of
Patient Description
Samples
Late Stage HGSOC at time of
45
diagnosis, pre-treatment
Early Stage HGSOC at time of
5
diagnosis, pre-treatment
Benign gynecological condition
50
(ovarian cyst)
Healthy volunteers from community
50
outreach

Age range
(Avg)(Median)
37-87
(63.6) (64)
43-66
(51.6) (47)
25-88*
(56.5) (55)
30-82
(55.4) (54)

Table 5.1: Patient population, n=150. Serum samples analyzed on western blot. *Indicates
age not available for 5 cases.
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Figure 5.1

Figure 5.1: Western Blot Images, Validation II, n=150.
Western blot of healthy control serum and early stage HGSOC serum diluted at 1:300 with 4
antigens in Validation II study. A) Secondary antibody anti-HIS tag IgG loading control. B)
Secondary antibody anti-human IgG. Scans quantified on Odyssey software; backgroundcorrected integrated intensity of anti-human IgG antibody (IRDye800) normalized as ratio to
anti-His tag antibody (IRDye700) per antigen.
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Figure 5.2

Figure 5.2: Western Blot Individual Antigen Reactivity, 4 Antigens, Validation II,
n=150.
A-D) Individual antigen plots for 4 antigens, TRIM21, NY-ESO-1, TP53, and PAX8 in
Validation II. E) Maximum value of TRIM21, NY-ESO-1, TP53, or PAX8 in Validation II.
The immunoreactivity as defined by the ratio of 800/700 is standardized for each antigen to
provide the threshold of Mean + 2(StdDev) for healthy controls, as indicated by the
horizontal line at Y=2.
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Table 5.2: Sensitivity/Specificity for TRIM21, NY-ESO-1, TP53, and PAX8, Validation
II.

Positive Threshold=2

Antigen
TRIM21
TP53
NYESO1
PAX8
TRIM21, TP53, NYESO1
TRIM21, TP53,
NYESO1, PAX8

Positive Threshold=3

Antigen
TRIM21
TP53
NYESO1
PAX8
TRIM21, TP53, NYESO1
TRIM21, TP53,
NYESO1, PAX8

Late Stage
HGSOC
(n=45)

Early
Stage
HGSOC
(n=5)

Sensitivity Sensitivity

Late and
Early
Stage
HGSOC
(n=50)
Sensitivity

Benign
(n=50)

Healthy
(n=50)

Specificity Specificity

Benign
and
Healthy
(n=100)
Specificity

0.38
0.16
0.20
0.09
0.51

0.20
0.00
0.00
0.00
0.20

0.36
0.14
0.18
0.08
0.48

0.90
0.96
0.94
0.98
0.80

0.96
0.96
1.00
0.96
0.92

0.93
0.96
0.97
0.97
0.86

0.53

0.20

0.50

0.80

0.88

0.84

Late Stage
HGSOC
(n=45)

Early
Stage
HGSOC
(n=5)

Late and
Early
Stage
HGSOC
(n=50)

Healthy
(n=50)

Benign
and
Healthy
(n=100)

Sensitivity Sensitivity

Sensitivity

Benign
(n=50)

Specificity Specificity

Specificity

0.24
0.16
0.20
0.04
0.49

0.20
0.00
0.00
0.00
0.20

0.24
0.14
0.18
0.04
0.46

0.98
1.00
0.98
0.98
0.96

1.00
0.98
1.00
1.00
0.98

0.99
0.99
0.99
0.99
0.97

0.49

0.20

0.46

0.94

0.98

0.96

Table 5.2: Sensitivity and specificity for TRIM21, NY-ESO-1, TP53, PAX8, evaluated on
western blot with n=150 sample set. Threshold (2)=Mean + 2(StdDev) for healthy controls,
threshold (3)=Mean + 3(StdDev) for healthy controls.
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not statistically significant at the 0.05 level (p-value=0.096 and p-value=0.369,
respectively, using a 2X2 chi-square contingency table with Yates correction).
Receiver Operating Characteristic (ROC) analysis resulted in area under the curve
(AUC) of 0.832 for Validation I and 0.701 for Validation II (Figure 5.3). For both sample
sets, TRIM21 individually provided the highest AUC: 0.671 in Validation I and 0.618 in
Validation II.
5.2.3. Reactivity in Early Stage HGSOC Samples
Although the HARS antigen was not evaluated on this entire n=150 sample set,
the 5 early stage HGSOC samples were processed with the HARS protein resulting in
1/5 positive samples. TRIM21 was the only other antigen positive in the 5 early stage
HGSOC samples; combining TRIM21 and HARS resulted in 2/5 early stage HGSOC
samples positive in this set.
5.2.4. Low Grade Serous Ovarian Cancer Samples
As low-grade serous ovarian cancer (LGSOC) can develop step-wise from
ovarian serous cystadenoma, it is a possibility that autoantibody positivity in the benign
cyst samples may indicate preneoplastic lesions [181, 187]. We evaluated 22 samples
from patients with early stage LGSOC with the antigens TRIM21, NY-ESO-1, TP53,
PAX8, and HARS.

1/22 early stage LGSOC samples were positive for TP53

autoantibodies and 1/22 samples were positive for TRIM21 autoantibodies. LGSOC
has a distinct protein expression and mutational profile from HGSOC however, and our
markers were selected with HGSOC samples.
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Figure 5.3

Figure 5.3: ROC Curve Analysis, Validation II, n=150.
ROC curve analysis for the combination of the 4 markers: TRIM21, NY-ESO-1, TP53, and
PAX8 in Validation II
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5.2.5. Stage Distributions Validation I and Validation II
Stage distributions for the two samples populations are shown in. Table 5.3.
Although Validation I set had a higher number of stage 4 cases than the Validation set,
within Validation I, Stage 3 sensitivity is 72% compared with sensitivity among stage 4
cases of 71%.
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Table 5.3: Antigen Reactivity by Tumor Stage for HGSOC samples.
Validation I, n=64
Stage Stage
Stage
1A
1B
#
3
1
Positive
Total
4
1
samples
%
0.75
1.00

Stage
1C

Stage
3A

Stage
3B

Stage Stage 3 Stage
3C
NOS
4A

3

1

2

22

1

3

3

4

9

1

3

31

1

3

5

6

0.33

1.00

0.67

0.71

1.00

1.00

0.60

0.67

TOTAL
Stage
#
Positive
Total
samples
%

Stage 1 Stage 3 Stage 4

Stage 3
All
or 4
Stages

7

26

10

36

43

14

36

14

50

64

0.50

0.72

0.71

0.72

0.67

Stage
1A

Stage
1C

Stage
3B

0

1

0

22

0

1

1

3

2

1

36

2

4

2

0.00

0.50

0.00

0.61

0.00

0.25

0.50

Validation II, n=50
Stage
#
Positive
Total
samples
%

Stage
#
Positive
Total
samples
%

Stage Stage 3 Stage 4
3C
NOS
NOS

TOTAL
Late
Stage 1 Stage 3 Stage 4 stage
NOS

Late
stage
NOS

Stage 3
All
or 4
Stages

1

22

1

1

24

25

5

39

4

2

45

50

0.20

0.56

0.25

0.50

0.53

0.50

NOS=Not otherwise specified

Table 5.3: Antigen Reactivity by Tumor Stage for HGSOC samples.

Stage Stage 4
4B
NOS
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6. CHAPTER 6: TRIM21 AUTOANTIBODIES IN HGSOC
6.1. Summary of TRIM21 Reactivity with HGSOC Sera
TRIM21 consistently showed superior reactivity in multiple patient sample
populations, including on line blots in section 1.1, on western blot and ELISA with a set
of n=36 samples in section 3.2, and on western blot in Validation I in section 5.2 and in
Validation II in section 6.2. TRIM21 was identified as a novel biomarker for ovarian
cancer, with the highest individual sensitivity of 33% for all HGSOC samples at 100%
specificity compared to healthy controls in Validation I, and 36% sensitivity at 96%
specificity in Validation II.
6.2. TRIM21 Function as Intracellular Pathogen Sensor and Potent Fc Receptor
TRIM21 consists of 4 domains: a RING domain involved in ubiquitination, B-box
domain, coiled-coiled domain, and a c-terminal PRY-SPRY domain which is an
immunoglobulin Fc receptor [94]. TRIM21 is the most potent mammalian Fc receptor.
The PRY-SPRY domain alone binds with ~200 nM affinity, but when it binds as a dimer
to the immunoglobulin heavy chain, the affinity is sub-nanomolar, at approximately 0.6
nM [94]. There are 68 members in the TRIM protein family, however only TRIM21 has
Fc binding ability [22]. This Fc binding function allows TRIM21 to neutralize antibodybound virus or bacteria. Binding of TRIM21 to an antibody-bound pathogen initiates
innate immune signaling as a multi-step process. It neutralizes the virus by targeting for
degradation and detection by RIG1 or cGAS, and activates NFKB and TLR signaling
[49].
The recent discovery that TRIM21 participates in neutralization of intracellular
antibody-bound virus or bacteria has prompted studies to take advantage of this activity
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for therapeutics. One group has demonstrated the ability of TRIM21 to disrupt tau
aggregation

using

anti-tau

antibodies,

with

potential

for

therapeutics

for

neurodegenerative diseases with protein aggregates [120]. Another technology has
been proposed for degradation of endogenous proteins has been engineered around
TRIM21 neutralization and is named the Trim-Away approach, which targets any protein
by introduction of the target-specific antibody and over-expression of TRIM21 [120].
Autoantibodies are targeted to the Fc-binding domain [22]. It has been proposed
that autoantibodies can be generated against TRIM21 when it is in complex with
antibody-bound pathogens. Burbelo et al. have generated mutant TRIM21 proteins that
are deficient in Fc-binding function, and demonstrated specific autoantibody binding to
these mutants [22]. Additionally, TRIM21 positive serum was blocked with TRIM21 and
other TRIM protein family members to demonstrate specific binding. The Fc binding
function of TRIM21 is conformation dependent; our studies utilized denatured protein.
Studies with native TRIM21 demonstrated a low level of background signal present in all
sample types, yet still observed specific TRIM21 autoantibodies in positive control sera
with reactivity that was significantly elevated compared with controls [22]. We have
demonstrated specific antibody binding by blocking a TRIM21 autoantibody positive
control serum sample (The Binding Site, San Diego, CA) with TRIM21 antigen, shown in
Figure 6.1.
6.3. Screening for TRIM21 Autoantibodies in Samples from Patients with Pelvic
Inflammatory Disease and other Benign Gynecologic Conditions.
To determine if TRIM21 autoantibodies can be detected in the setting of pelvic
infection and inflammation, we evaluated 12 serum samples from patients that had self-
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Figure 6.1

Figure 6.1: Western Blot Evaluating TRIM21 Autoantibody Binding Specificity
Positive control patient serum, sample ID:BX104 (The Binding Site, San Diego, CA) was
pre-incubated with purified antigen prior to incubation on western blot. Without preincubation with antigen, BX104 reacts with HARS and TRIM21, and does not react with
T712A on western blot. Pre-incubation of BX104 with HARS specifically reduces reactivity
with HARS, pre-incubation of BX104 with TRIM21 specifically reduces reactivity with
TRIM21, and pre-incubation of BX-104 with T712A has no effect on HARS or TRIM21 on
western blot.

106
reported pelvic inflammatory disease (PID).

Patients with PID have bacterial or viral

infection of the pelvis. None of the 12 samples displayed reactivity with TRIM21 on
western blot (Figure 6.2). TRIM21 was detected in 5/50 benign ovarian cyst samples in
Validation I and 5/50 ovarian cyst samples in Validation II.
6.4. TRIM21 Reactivity in Ovarian Cancer Serum Samples
In a study of HGSOC serum samples that utilized high-density programmable
protein microarrays containing 10,247 antigens, TRIM21 was identified as one of the top
39 candidate tumor antigens, which passed three rounds of serum screening in
independent sample sets [92].

From the top 39 candidate antigens, the authors

selected a final panel of 11 antigens, which did not include TRIM21. Performance of
TRIM21 relative to the top 39 antigens is shown in Table 6.1. TRIM21 has equal or
greater performance than several antigens included in the final panel of 11 antigens.
These studies were performed on a rapid ELISA platform, and in our experiments
TRIM21 was undetectable o ELISA in 10 HGSOC serum samples that reacted with
TRIM21 on western blot.
6.5. TRIM21 Autoantibodies in Other Cancer Types
TRIM21 has previously been reported as a biomarker for esophageal squamous
cell carcinoma (ESCC) and basal-like breast cancer [100, 185].

To identify

autoantibody biomarkers for ESCC, a SEREX library created with cDNA from an ESCC
cell line and screened with ESCC sera.

TRIM21 was identified from the SEREX

screening and reactivity with patient serum was confirmed on ELISA and western blot
[100]. TRIM21 autoantibodies were also detected in colon, gastric, and breast cancer
serum samples [100]. In a protein array screen of 10,000 human proteins, TRIM21 was
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selected in a set of 71 candidate autoantibody biomarkers for basal like breast cancer
[185]. After 3 rounds of ELISA screening with basal like breast cancer sera, TRIM21
was identified as a top marker in a set of 13 markers [185].
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Figure 6.2

Figure 6.2: Western Blot: 12 PID Serum samples with TRIM21 and T712A. Positive
control BX sera (The Binding Site, LLC), positive for TRIM21 and HARS is shown in the
last column, with two HARS antigens, HARS1 (Novus Biologicals) and HARS2 (purified in
lab), as well as the TRIM21 antigen which was included on PID samples 1-12. Negative
control antigen T712A was included on each membrane incubated with patient serum. Serum
samples diluted 1:300 in 5% milk.
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Table 6.1 TRIM21 Reactivity on Rapid ELISA
A.

Healthy Threshold (Mean + 2 Std. Dev)
Benign Threshold (Mean + 2 Std. Dev)
per Antigen
B.
per Antigen
Cancer Benign Healthy
Cancer Benign Healthy
Antigens
Antigens
(n=29) (n=30) (n=28)
(n=29) (n=30) (n=28)
NUDT11
8
1
1
NUDT11
8
1
2
STYXL1
7
2
0
TRIM39
7
1
4
PVR (B)
6
2
0
STYXL1
4
2
0
CA4
5
2
0
PVR (B)
4
1
0
POMC
5
4
1
KSR1
4
3
3
UHMK1
4
4
0
CA4
3
2
0
TRIM21
3
3
0
NY-ESO-1
3
2
0
NY-ESO-1
3
4
1
TRIM21
2
1
0
TP53
2
1
1
P53
2
1
0
NXF3
2
4
0
POMC
2
1
0
ICAM3
1
0
1
ICAM3
1
0
1
TRIM39
1
0
1
UHMK1
1
2
0
SAP18
3
2
1
NXF3
1
2
0
TNFRSF11B
3
2
0
TNFRSF11B
2
1
0
AKT1
3
3
1
KCNH2
1
2
2
BRD3
3
1
2
CHRM4
1
1
3
PRMT5
2
2
0
MAP3K7
1
1
1
MLH1
2
0
1
PVR-A
1
1
2
TUBB
1
3
1
TIMP3
1
1
2
KCNH2
1
0
2
SAP18
1
2
0
CHRM4
1
1
2
PRMT5
1
2
0
LRRFIP1
1
1
1
NDUFA3
1
1
2
WSB1
1
2
2
AKT1
1
1
1
ELOVL2
1
0
2
MIB2
4
1
5
AARS
1
2
1
BRD3
3
1
3
MIB2
1
0
2
NPTX2
3
3
3
KSR1
0
0
1
MLH1
3
2
4

Table 6.1: Analysis of Supplemental Data from: Katchman BA, Chowell D, Wallstrom G, et
al. Autoantibody biomarkers for the detection of serous ovarian cancer. Gynecol Oncol.
2017;146(1):129–136. Thresholds calculated using values from A) healthy controls and B)
benign samples. Of the top 39 antigens selected from original 10,247 antigens, shown are
those Positive count indicates sample value > threshold. Antigens highlighted in yellow
indicated final panel of 11 antigens selected by authors. TRIM21 highlighted in turquoise,
shows equal or greater performance to the 11 antigens highlighted in yellow.
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7. CHAPTER 7: Discussion
7.1. Ovarian Cancer Early Detection Biomarker Performance
Early detection of ovarian cancer has the potential to improve patient outcome,
as late stage disease is associated with widespread metastasis, complication of
surgery, and drastically reduced prognosis. Screening for ovarian cancer is currently
not recommended for the general population, and there are no approved tests or
markers for early diagnosis. One method which has been evaluated in clinical trials is
ROCA, which consists of a two-step test that involves measurement of circulating
antigen CA125 at an increased level relative to each patient’s baseline interpreted with
patient age, followed by imaging such as TVUS. Having a sequential test process of
orthogonal measurements reduces the rate of false-positives. However, the initial step
of CA125 detection in this two-step process misses approximately 20% of all cases as
20% of all ovarian cancers do not shed CA125 [166]. Moreover, 40-50% of early stage
cases with low-volume disease do not shed CA125 at levels high enough to be detected
[194].

Autoantibodies to tumor antigens, produced at small tumor volumes, can be

combined with serum screening of CA125 to improve sensitivity in early detection.
TP53 autoantibodies have been detected in 16% of cases that were not detectable with
CA125 in preclinical samples [194].

We have found that NY-ESO-1 and TRIM21

autoantibodies are present in a higher percentage of early stage samples than
autoantibodies to TP53.
7.1.1. PPV Calculations
The positive and negative predictive values were estimated using a range of
OVCA prevalence representing 10 to 20-fold increases relative to the general
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population level risk (1/2500). We combined values from Validation I and Validation II
for analysis of n=214 HGSOC cases and n=100 healthy cases for the three markers
TRIM21, TP53, and NY-ESO-1, resulting in a sensitivity of 52% with a specificity of
98%.

For a 10-fold increase in prevalence of OVCA (0.4%) relative to population

prevalence, using a sensitivity of 52% and a specificity of 98%, we estimated the PPV
and NPV.

PPV at 10, 15, or 20-fold increased prevalence was 9.4%, 13.5%, and

17.2%, respectively, with NPV 99.8%, 99.6%, and 99.7%.

Additionally, in practice,

these biomarkers would be combined with CA125 values presumably resulting in
increased sensitivity, followed by TVUS, which would result in increased specificity.
These results indicate that the panel could be useful for screening in a high-risk
population, including BRCA1/2 mutation carriers and women with a family history of
OVCA.
7.1.2. High-risk population
In three recent studies within the population of women with an increased risk of
ovarian cancer that evaluated CA125 using the ROCA method at intervals of 3 or 4
months, an increase in detection sensitivity for early stage tumors was observed [147,
166].

The goal of identifying autoantibody biomarkers is both to complement CA125,

and to provide lead-time to CA125 detection. The serum set used in this study had
limited samples with data for CA125 values. Autoantibodies to TP53 have been shown
by Yang et al. to be elevated in pre-diagnostic patient samples up to 11 months before
detection of CA125, and in samples taken 23 months before diagnosis of ovarian
cancer for cases that were not detected by CA125 [194].

In our cohort anti-TP53

antibodies were present in 2/19 early stage samples. The markers TRIM21, HARS, NY-
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ESO-1, and PAX8, detected 9/19 additional early stage samples. Addition of these
markers to TP53 improves sensitivity, and may improve lead-time, thus addressing the
ultimate goal of a diagnosis at an earlier stage. Determining whether TRIM21, HARS,
NY-ESO-1, and PAX8 autoantibodies are also detectable in addition to TP53 in prediagnostic sera will be a critical step in evaluating these biomarkers for clinical use.
Early detection of HGSOC has potential to provide a mortality reduction [86].
7.2. Autoantibodies as predictors of neurologic irAEs
In addition to early detection, this work also describes the frequency of
paraneoplastic antibodies in HGSOC patients without a neurological syndrome. In lung
cancer, the frequency of the anti-Hu antibody has been reported to be 16-25% in
patients without a syndrome [93]. Assessing the frequency of autoantibodies in cancers
associated with paraneoplastic syndromes can contribute to understanding the etiology
of paraneoplastic syndromes.
With increasing success of immunotherapy for cancer treatment, determining if
patients can be stratified into those likely develop a paraneoplastic syndrome as a result
of immunotherapy will be critical for optimal patient care.

Baseline levels of

autoantibodies have been assessed for their utility to predict risk of neurologic irAEs
with immune-checkpoint therapy [10]. As described in section 1.2.3., immunotherapy
strategies are being developed for ovarian cancer including CAR-T cell, vaccines,
CTLA-4 and PD-1-inhibiton in combination with Parp-inhibition. Although markers such
as CDR2 and CDR2L did not provide early detection diagnostic ability, they may serve
as markers to identify patients undergoing anti-CTLA4 checkpoint blockade therapy who
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may be at risk of developing neurologic irAEs, particularly paraneoplastic cerebellar
degeneration.
7.3. Conformational Considerations
The antigens used in this study were purified form E. coli and were denatured
with both urea and heat. These methods limit the ability to detect antibodies against
conformation-dependent epitopes. Production of protein in E. coli results in lack of
posttranslational modifications and proper folding as observed in human cells [88].
Additionally, treatment with heat and urea results in unfolded protein. Follow up studies
to determine if native protein will detect additional cases are warranted.

Antibody-

antigen binding is also limited due to solid surface immobilization of our antigen, which
can restrict epitope availability [13]. Due to variability in performance between antibody
detection platforms, confirmation of positive results on a separate platform may be
necessary [172].
Additionally, autoantibodies can be in complex with antigen has been described
for ovarian cancer biomarkers HE-4 and CA125 [40, 195].

In the case of CA125,

presence of CA125 immune complexes were associated with decreased antigen
concentration, presumably due to assay interference [40].

Whether antigen-

autoantibody complexes hamper autoantibody detection can be assessed with pretreatment of samples to dissociate complexes.
7.4. Sources for Novel Autoantigen Discovery
Rather than screening serum against protein libraries, novel methods of antibody
discovery aim at directly sequencing the autoantibody content from serum samples.
There are multiple platforms for sequencing of the B-cell antibody receptor, however
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results have been shown to not accurately represent circulating IgG [21].
Supplementing with protein-level data is necessary to identify relevant antibodies [34].
One approach involves top-down mass spectrometry analysis of intact immunoglobulins
purified from serum.

IgG can also be digested and the Fab-fragment which binds

antigen is then sequenced, with bottom-up data analysis with alignment of sequences to
a reference library. Top-down and bottom-up approaches can be integrated for a more
complete analysis of the antibody repertoire in a single sample [48]
Sources of antibody discovery include samples from patients that were seronegative for existing biomarkers. This approach has been used for discovery of novel
paraneoplastic autoantibodies that were common among samples sero-negative for the
classical markers [102, 174]. Within our Validation I and Validation II sample sets, the
HGSOC samples that did not react with our panel of 4 antigens could be pooled as a
discovery sample resource.
The precursor of the majority of high-grade serous ovarian cancers is widely
recognized as serous tubal intraepithelial carcinoma.

These lesions have been

identified in the fallopian tubes of patients who underwent RRSO. Gene expression
profiling has identified HGSOC signatures to better correlate with normal fallopian tube
than ovarian surface epithelium [50]. Tissue from resected serous tubal intraepithelial
carcinoma are excellent sources for biomarker discovery as they represent the earliest
phases of tumor progression which have been reported to be present years prior to
development of HGSOC.
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8. CHAPTER 8: Conclusions and Future Directions
The goal of this dissertation work was to evaluate the serum autoantibody levels
to paraneoplastic antigens in HGSOC in order to identify candidate biomarkers for early
detection. A panel of autoantibody biomarkers can be useful in complementing current
screening methods for the early detection of ovarian cancer in women with an increased
genetic risk of ovarian cancer.

Our laboratory has previously identified epitopes

reactive with ovarian cancer patient serum using phage-display technology.

As

described in Chapter 3, we identified phage-borne epitopes that were homologous to
antigens associated with paraneoplastic neurological syndromes. In Chapter 3, the
presence of paraneoplastic antibodies in HGSOC sera was evaluated. We screened a
panel of 20 paraneoplastic antigens against patient serum samples and identified
candidate antigens reactive with HGSOC sera: TRIM21, HARS, AlaRS, SRP, CDR2,
and HuD. We further sub-cloned full-length HIS-tagged protein of these markers as well
as 4 epitopes with homology to HARS, TRIM21, SRP, and HuD. These proteins were
purified from E. coli using HIS tag and T7 tag, and evaluated on western blot and ELISA.
In Chapter 4, we performed a screening of n=164 patient samples against 9 selected
antigens on western blot and ELISA: TRIM21, HARS, CDR2, CDR2L, CORTACTIN,
NY-ESO-1, TP53, P3F10, and T712A. Autoantibodies against the HARS antigen were
more frequently detected in early stage sera than in late stage sera, and autoantibodies
against TRIM21 were observed at the highest frequency.

An additional 3 tumor-

associated antigens were processed with the n=164 sample set: BRCA1, CMYC, and
PAX8. We determined that the combination of 4 markers: TRIM21, NY-ESO-1, TP53,
and PAX8, provide sensitivity of 67% at 95% specificity. In Chapter 5, we validated this
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panel of 4 markers on an independent serum set consisting of n=150 patient serum
samples on western blot. In this study, the combination of TRIM-21, NY-ESO-1, TP53,
and PAX8 provided a sensitivity of 46% with 98% specificity.
This study is the first to demonstrate accuracy of TRIM21 autoantibodies as a
biomarker for HGSOC in a large-scale screening. TRIM21 was previously identified as
a relevant tumor-associated antigen in basal-like breast cancer, ESCC, and serous
ovarian cancer through proteomics-based discovery. In Validation I and Validation II,
autoantibodies to TRIM21 were detected at 33% and 36% sensitivity in all HGSOC
cases with 100% and 96% specificity compared to healthy controls. Somatic mutations
in TP53 are found in in 96% of HGSOC cases [37]; autoantibodies to TP53 in HGSOC
can be detected against the wild type protein as a polyclonal response [91]. NY-ESO-1
is an immunotherapy target for ovarian cancer with numerous trials evaluating vaccines
targeting NY-ESO-1 as well as adoptive transfer of NY-ESO-1 specific T-cells [131].
PAX8 is expressed in the majority of HGSOCs [20]. The present study is the first to
detect anti-PAX8 autoantibodies.
These

studies

provide

evidence

that

autoantibodies

associated

with

paraneoplastic syndromes can be identified in the serum of patients diagnosed with
cancer who do not present with paraneoplastic symptoms. We found that although a
number of paraneoplastic antibodies are present in HGSOC sera, the anti-TRIM21
antibodies provided the best sensitivity and specificity for use in early detection.
Combination of TRIM21 with established tumor antigens NY-ESO-1 and TP53
enhanced sensitivity and specificity.

Furthermore, we demonstrated that anti-PAX8

autoantibodies are present in the serum of patients with ovarian cancer.
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The identified autoantibody biomarkers should be validated with pre-diagnostic
serum samples to determine the time prior to diagnosis that the autoantibodies can be
detected. Another area for further study is to expand the current panel by identification
of autoantibodies in those serum samples that did not react with our set of 4 markers.
Additionally, assessment of these markers in companion with CA125 will be performed
with the Validation I and Validation II sample sets, which is essential for determination of
clinical utility of these markers.
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ABSTRACT
EVALUATION OF AUTOANTIBODIES TO PARANEOPLASTIC ANTIGEN AS EARLY
DETECTION BIOMARKERS FOR HIGH-GRADE SEROUS OVARIAN CANCER
by
LAURA CATHERINE HURLEY
May 2020
Advisor: Dr. Michael A. Tainsky
Major: Cancer Biology
Degree: Doctor of Philosophy
The majority of ovarian cancer cases are diagnosed at an advanced stage
metastatic disease with poor prognosis due to non-specific symptoms and lack of early
detection methods.

This study evaluates autoantibodies against tumor antigens to

identify candidate biomarkers for the early detection of ovarian cancer in high-risk
women. We examined antigens associated with paraneoplastic neurological synromes,
which are autoimmune diseases that develop when the unregulated immune response
against a tumor also targets healthy cells. Notably, a set of autoantibodies have been
previously detected in paraneoplastic neurological syndrome patients with concurrent or
subsequent diagnosis of ovarian cancer, identifying highly immunogenic antigens in the
tumor.
In this dissertation work, we have detected paraneoplastic antibodies present in
serum samples from patients with high-grade serous ovarian cancer (HGSOC) without
paraneoplastic neurological syndromes using line blots, western blots, and ELISA.

A

panel of five paraneoplastic antigens (HARS, TRIM21, COR, CDR2, CDR2L) along with
2 established tumor antigens (NY-ESO-1, p53) were purified from E. coli for screening
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on western blot and ELISA.

Screening was performed with a patient serum set

consisting of: 50 late stage HGSOC, 14 early stage HGSOC, 50 benign ovarian cyst,
and 50 healthy volunteer samples. On western blot, the paraneoplastic antigen with the
best performance was TRIM21 with 35% sensitivity. Combining TRIM21 with p53 and
NY-ESO-1 yielded a sensitivity of 60% with 90% specificity. In the early stage HGSOC
sample set, HARS demonstrated 31% sensitivity individually, and 46% sensitivity with
98% specificity when combined with p53 and NY-ESO-1. The identified markers will
were tested in an independent validation serum set consisting of n=150 samples. The
work in this dissertation identified the paraneoplastic antigen TRIM21 that can enhance
autoantibody biomarker panels for the early detection of HGSOC.
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